1
EXHIBIT 4.02
AMENDED AND RESTATED
MASTER RIGHTS AGREEMENT
This Master Rights Agreement (the "Agreement") is made and
entered into as of the 31st day of October, 1995 by and among AtheroGenics,
Inc., a Georgia corporation (the "Company"), Alliance Technology Ventures,
Limited Partnership, a Delaware limited partnership ("Alliance"), ATV/GP
Parallel Fund, Limited Partnership, a Delaware limited partnership ("ATV/GP"),
ATV/MFJ Parallel Fund, Limited Partnership, a Delaware limited partnership
("ATV/MFJ"), Intelligent Systems Corporation, a Georgia corporation
("Intelligent Systems"), International Murex Technologies Corp., a company
organized under the laws of British Columbia, Canada ("Murex"), Sanderling III
Limited, a Cayman Islands limited partnership ("Sanderling Limited"), Sanderling
Venture Partners III, a California limited partnership, ("Sanderling Venture"),
Sanderling III Biomedical, a California limited partnership ("Sanderling
Biomedical"), Sanderling Ventures Management, a California limited partnership,
("Sanderling Management") and New York Life Insurance Company, a New York
corporation ("NY Life").
AGREEMENT
In consideration of the following mutual covenants and
agreements, and subject to the terms and conditions set forth herein, the
parties hereto agree as follows:
ARTICLE I.
1.1 Definitions. The following definitions shall be applicable to
the terms set forth below as used in this Agreement:
(a) "Affiliates." The term "Affiliate" shall mean, with
respect to any Person, any other Person which directly, or indirectly through
one or more intermediaries, controls, is controlled by or is under common
control with such Person.
(b) "Articles." The term "Articles" shall mean the
Company's Articles of Incorporation, as amended from time to time.
(c) "Board." The term "Board" shall mean the Board of
Directors of the Company.
(d) "Budget." The term "Budget" shall have the meaning
set forth in Section 2.1(d) hereof.
2
(e) "Commission." The term "Commission" shall mean the
Securities and Exchange Commission or any other federal agency at the time
administering the federal securities laws.
(f) "Common Stock." The term "Common Stock" shall mean
the Company's Common Stock as constituted on the date hereof.
(g) "Company's Notice." The term "Company's Notice" shall
have the meaning set forth in Section 3.3 hereof.
(h) "Conversion Shares." The term "Conversion Shares"
shall mean any Common Stock issued or issuable upon conversion of the Preferred
Stock held by the Investors.
(i) "Equity Securities." The term "Equity Securities"
shall have the meaning set forth in Section 2.3 hereof.
(j) "GAAP." The term "GAAP" shall mean generally accepted
accounting principles (as such principles are applied in the United States of
America as of the date of the financial statement with respect to which the term
is used), consistently applied.
(k) "Initiating Holders." The term "Initiating Holders"
shall mean the holders of Registrable Stock initially requesting registration of
Registrable Stock pursuant to Section 3.1 of this Agreement.
(l) "Investors." The term "Investors" shall mean
Alliance, ATV/GP, ATV/MFJ, Intelligent Systems, Murex, Sanderling Limited,
Sanderling Venture, Sanderling Biomedical, Sanderling Management and NY Life,
their respective successors and assigns and any other holder of Preferred Stock
or of warrants, options or other rights to acquire Preferred Stock who by
amendment is added as a party to this Agreement.
(m) "Investors' Notice." The term "Investors' Notice"
shall have the meaning set forth in Section 3.3 hereof.
(n) "Long-Form Registration Statement." The term
"Long-Form Registration Statement" shall mean a registration statement on Form
X-0, Xxxx X-0, Form SB-1 or Form SB-2, or any similar form of registration
statement adopted by the Commission from and after the date hereof.
(o) "Permitted Transferees." The term "Permitted
Transferees" of an Investor shall mean (i) any other Investor; (ii) any
Affiliate of any Investor; (iii) any one or more members of a class consisting
of the spouse, children and grandchildren of an Investor, or a trust for the
benefit of any one or more members of such class; or (iv) any shareholder or
2
3
partner of any non-natural Investor upon a pro rata distribution by a
partnership to its partners or otherwise upon the dissolution or liquidation of
the non-natural Investor.
(p) "Person." The term "Person" shall mean any
individual, firm, corporation, partnership, trust, joint venture, governmental
authority or other entity, and shall include any successor (by merger or
otherwise) of such entity.
(q) "Preferred Stock." The term "Preferred Stock" shall
mean the Company's Series A Convertible Preferred Stock and Series B Convertible
Preferred Stock.
(r) "Prospective Sellers." The term "Prospective Sellers"
shall have the meaning set forth in Section 3.6(a)(ii) hereof.
(s) "Register." The terms "register," "registered" and
"registration" refer to a registration effected by preparing and filing a
registration statement in compliance with the Securities Act.
(t) "Registrable Stock." The term "Registrable Stock"
shall mean (i) any Common Stock issued or issuable upon conversion of the
Preferred Stock held or acquired by any of the Investors; (ii) any Common Stock
issued or issuable with respect to the Conversion Shares by reason of a stock
dividend or stock split or in connection with a combination of shares,
recapitalization, merger, consolidation or other reorganization, and (iii) any
other shares of Common Stock now held or hereafter acquired by Persons holding
the securities described in clauses (i) and (ii) above. A Person shall be deemed
to be a holder of Registrable Stock when such Person has a right to acquire such
Registrable Stock (whether by conversion or otherwise) regardless of whether
such acquisition has actually been effected. Each share of Registrable Stock
shall continue to be Registrable Stock in the hands of each subsequent holder
thereof subject to the limitations set forth in Section 3.14 hereof; provided
that each share of Registrable Stock shall cease to be Registrable Stock when
transferred (x) to any Person who is not a Permitted Transferee or if the
transfer does not comply with the terms of this Agreement, (y) pursuant to a
registered public offering, or (z) in accordance with Rule 144 promulgated by
the Commission under the Securities Act.
Notwithstanding anything to the contrary herein, the term
"Registrable Stock" (solely for the purposes of Sections 3.3 to 3.8, inclusive,
3.10 and 3.13) shall include (i) any Common Stock outstanding on the date hereof
and (ii) any Common Stock issued out of the Reserved Shares. Moreover, the
registration rights for such Registrable Stock described in the immediately
preceding sentence shall not be transferable, except in a transfer to a
Permitted Transferee.
3
4
(u) "Requesting Holders." The term "Requesting Holders"
shall have the meaning set forth in Section 3.1(c) hereof.
(v) "Reserved Shares." The term "Reserved Shares" shall
mean shares of Common Stock reserved for issuance to directors, officers,
employees and consultants upon the exercise of outstanding or future options of
the Company.
(w) "Securities Act." The term "Securities Act" shall
mean the Securities Act of 1933, as amended.
(x) "Short-Form Registration Statement." The term
"Short-Form Registration Statement" shall mean a registration statement on Form
S-3 or any similar form of registration statement adopted by the Commission from
and after the date hereof.
1.2 Additional Definitions. In addition to the foregoing,
capitalized terms used in this Agreement and not otherwise defined in this
Article I shall have the meanings so given to such terms herein.
ARTICLE II.
COVENANTS OF THE COMPANY AND THE INVESTORS
2.1 Accounting; Financial Statements and Other Information;
Inspection Rights.
(a) Accounting. The Company shall maintain and cause each
of its subsidiaries to maintain a system of accounting established and
administered in accordance with GAAP and shall set aside on its books and cause
each of its operating subsidiaries to set aside on its books all such proper
reserves as shall be required by GAAP.
(b) Financial Statements. So long as there are any shares
of Preferred Stock outstanding and an Investor holds not less than 7.5% of the
outstanding Preferred Stock, the Company shall deliver to each such Investor,
within 90 days after the end of each fiscal year of the Company, a consolidated
and consolidating balance sheet of the Company and its subsidiaries as of the
end of such year and consolidated and consolidating statements of operations,
cash flows and stockholders' equity (deficit) of the Company and its
subsidiaries for such year, setting forth in each case comparisons to the Budget
and the previous fiscal year, all in reasonable detail and accompanied by the
opinion thereon of independent public accountants of national standing, which
opinion shall not be qualified and shall state that the financial statements
were prepared in accordance with GAAP applied on a basis consistent with that of
the previous fiscal year, fairly present the consolidated financial condition of
the Company as of the date thereof and for the periods covered thereby and that
the audit by such accountants in
4
5
connection with such financial statements has been made in accordance with
generally accepted auditing standards.
(c) Additional Information. So long as there are any
shares of Preferred Stock outstanding and an Investor Stock holds not less than
7.5% of the outstanding Preferred, the Company shall deliver to each such
Investor:
(i) within 30 days after the end of each of (A)
the monthly accounting periods, and (B) the quarterly accounting periods in each
fiscal year of the Company, a consolidated and consolidating balance sheet of
the Company and its subsidiaries as of the end of each such period, and
consolidated and consolidating statements of operations, cash flows and
stockholders' equity (deficit) of the Company and its subsidiaries and changes
in consolidated and consolidating financial position of the Company and its
subsidiaries for each such period and for the period from the beginning of the
current fiscal year to the end of such monthly or quarterly period, setting
forth in each case comparisons to the Budget and the corresponding periods of
the previous fiscal year, all in reasonable detail and certified by the chief
financial officer of the Company;
(ii) concurrently with the delivery of each of
the financial statements referred to in Sections 2.1(b) and 2.1(c)(i) above, an
executed written report by the chief executive officer of the Company with
respect to the operations of the Company during the period covered by such
statements, including a discussion, in reasonable detail, of operating results
versus Budget and of problems and achievements versus goals and milestones and
setting forth goals and milestones for the ensuing month, quarter and year;
(iii) within 90 days after the end of each fiscal
year of the Company, a copy of any management letter delivered to the Company by
its independent public accountants with respect to such year;
(iv) promptly (but in any event within ten days)
after any material adverse event or circumstance affecting the Company or any of
its subsidiaries (including, but not limited to, the filing of any material
litigation against the Company or any of its subsidiaries and the discovery that
the Company or any of its subsidiaries is not, or with the passage of time will
not be, in compliance with any provision of this Agreement, its Bylaws, the
Articles or any other material agreement of the Company or any of its
subsidiaries), a notice specifying the nature and period of existence thereof,
and the actions the Company has taken and/or proposes to take with respect
thereto; and
(v) promptly (but in any event within ten days)
after transmission thereof, copies of any general communication from the Company
or any of its subsidiaries to its stockholders, directors or the financial
community at large, and any reports filed by the Company or any of its
subsidiaries with any securities exchange, the National Association of
Securities Dealers, Inc., any state official or agency charged with securities
regulation, the
5
6
Commission or any other governmental agency, domestic or foreign (including,
without limitation, any correspondence between the Company or any of its
subsidiaries and any of the foregoing which contains information materially
adverse to the Company or any of its subsidiaries).
(d) Annual Budget.
(i) Prior to each December 31, the Company shall
prepare a Budget (the "Budget") for each succeeding 12-month period commencing
each subsequent January 1, which shall meet the approval of the Board. The
initial draft of the Budget will be prepared by the chief executive officer of
the Company and submitted to all Board members at least 15 days prior to the
meeting at which it is to be considered and in no event later than November 1st
of each year. The Budget shall contain the current business and marketing plans
of the Company for the 12-month period covered by it, including but not limited
to, cash flow and pro forma profit and loss statements for each month included
in such period. The Company agrees to use its best efforts to conduct its
business in conformity with the Budget.
(ii) At each meeting of the Board, operating
management will report on the receipts and expenditures of the Company as of a
date reasonably close to the date of the meeting and will recommend for action
by the Board any changes in the Budget which it considers necessary or
appropriate. Unless provided for in the Budget, no expenditure may be made by or
on behalf of the Company without action by the Board.
(iii) The Budget may be amended or otherwise
modified by the Board at such time or times as the Board deems appropriate.
(iv) So long as there are any shares of Preferred
Stock outstanding and an Investor holds not less than 7.5% of the outstanding
Preferred Stock, the Company shall furnish to each such Investor (in person or
by first-class mail) a copy of such Budget at least 30 days prior to the
commencement of the period covered by such Budget.
(e) Inspection Rights. The Company shall permit any
Investor or any representative designated by any Investor, at such Investor's
expense, to visit and inspect any of the properties of the Company or any of its
subsidiaries, including its and their books of account (and to make copies
thereof and to take extracts therefrom), and to discuss its and their affairs,
finances and accounts with its and their officers or employees and with
representatives of the Company's lenders, all at such reasonable times and as
often as may be reasonably requested; provided that such rights shall be
exercised in a manner so as not to materially and adversely disrupt the ordinary
course of business of the Company or any of its subsidiaries.
(f) Limitation of Rights. The rights of the Investors to
receive the information and conduct any inspections provided for in this Section
2.1 are subject to the right of the Company, prior to any such receipt of
information or inspection by any person, to demand
6
7
that such person hold all such information confidential and sign a
confidentiality agreement in a form mutually acceptable to the Company and the
Investors ("Confidentiality Agreement"). The receipt by any third person of such
information shall be subject to the prior receipt by the Company of a signed
Confidentiality Agreement from that third person.
2.2 Right of First Refusal for Issuance of Equity
Securities.
(a) If the Company determines to issue any
additional shares of its capital stock, or warrants, options, rights or other
securities convertible into its capital stock (collectively, the "Equity
Securities"), from and after the date of this Agreement for the purpose of
financing its business, the Company shall first give each of the Investors then
holding Preferred Stock the right to purchase such Equity Securities by
delivering to them a written offer which shall state the price and other terms
and conditions of the proposed issuance. If the Company proposes to issue the
Equity Securities for consideration other than solely cash and/or promissory
notes, the offer to the Investors then holding Preferred Stock shall, to the
extent of such consideration, permit such Investors to pay in lieu thereof, cash
equal to the fair market value of such consideration, and the offer shall state
the Company's estimate of such fair market value. The Board shall fix the period
of the offer which shall be a minimum of 30 days or such longer period as is
necessary to determine the fair market value of the consideration referred to in
the preceding sentence. Each Investor then holding Preferred Stock shall have
the right to assign any of the rights such Investor may have to purchase Equity
Securities under this Section 2.2 to any Permitted Transferee.
(b) An Investor then holding Preferred Stock may
accept an offer only by giving written notice to the Company before the offer
expires that such Investor has accepted the offer to purchase some or all of the
securities offered (the "Accepted Securities"); provided, however, that the
maximum number or amount of securities such Investor shall be entitled to
purchase shall be equal to that number or amount of securities to be issued
multiplied by a fraction, the numerator of which shall be the aggregate number
of Conversion Shares to which such Investor is entitled and the denominator of
which shall be the aggregate number of shares of voting capital stock of the
Company then outstanding. Notwithstanding the foregoing, any such Investor may,
at the time it accepts the offer, subscribe to purchase any or all securities
offered ("Oversubscription Securities") which may be available as a result of
the rejection, or partial rejection, of the offer by other such Investors. All
Oversubscription Securities shall be allocated on a pro rata basis among those
Investors subscribing to purchase them. If any such Investor declines to
purchase all or part of such Investor's pro rata allocation of Oversubscription
Securities, any remaining Oversubscription Securities shall be offered, on a pro
rata basis, to those Investors electing to purchase Oversubscription Securities.
The sale of Oversubscription Securities shall continue pursuant to the process
set forth in the immediately preceding sentence until all of the Equity
Securities have been purchased by the Investors or until no Investor desires to
purchase any remaining Oversubscription Securities.
7
8
Promptly following the expiration of the offer, the Company
shall allocate the securities subscribed for among the Investors then holding
Preferred Stock accepting or partially accepting the offer (the "Subscribing
Holders") in the manner described in the immediately preceding paragraph and
shall by written notice (the "Acceptance Notice") advise all Subscribing Holders
of the number or amount of securities allocated to each of the Subscribing
Holders. Within ten days following receipt of the Acceptance Notice, each of the
Subscribing Holders shall deliver to the Company payment in full for the
Accepted Securities purchased by it against delivery by the Company to each
Subscribing Holder of a certificate or certificates evidencing the Accepted
Securities purchased by it.
To the extent the offer is not subscribed in full by the
Investors then holding Preferred Stock, the Company may, for a period of 90 days
thereafter, issue and sell the unaccepted securities, or any of them, at the
same price, and upon the other terms and conditions specified in such offer, to
any Person or Persons.
(c) Notwithstanding the provisions of this Section 2.2,
the Company shall not be required to first offer the Equity Securities to
Investors holding Preferred Stock if:
(i) the issuance is pursuant to the conversion
of any shares of the Preferred Stock;
(ii) the Company proposes to issue Reserved
Shares, or nontransferable options to purchase Common Stock, for cash only, to
its officers or employees, or officers or employees of any of its subsidiaries,
or to outside consultants or contractors in connection with services performed
for the Company, pursuant to employment or compensation plans or other
arrangements approved by the Company's Board, provided the total of all such
shares does not exceed 800,000 shares;
(iii) the issuance is in connection with any stock
split, stock dividend or recapitalization of the Company;
(iv) the issuance is pursuant to an underwritten
public offering;
(v) the issuance is pursuant to the acquisition
of another company;
(vi) the issuance is to Pheonix Growth Capital
Corp., or its Affiliate or assignee, in connection with an equipment lease
facility for the Company, provided the total of all such shares does not exceed
12,500 shares;
(vii) the issuance is to International Murex
Technologies Corporation, or its Affiliate or assignee, in connection with the
Company's rental obligations under that certain Sublease Agreement dated March
1, 1995 or in connection with certain capital
8
9
leasehold improvements made to the leased premises pursuant to that certain
Letter Agreement dated September 11, 1995, provided the total of all such shares
does not exceed 200,294 shares;
(viii) the issuance is to Emory University pursuant
to the terms of that certain Common Stock Purchase Agreement dated January 11,
1995; or
(ix) the issuance is to one or more of the
holders of the Preferred Stock upon the exercise of warrants to purchase shares
of Series B Convertible Preferred Stock issued pursuant to that certain Series B
Convertible Preferred Stock Purchase Agreement of even date herewith.
2.3 Reserved Shares.
(a) The Reserved Shares shall be issued from
time to time to directors, officers, employees and consultants of the Company
under such arrangements, contracts or plans as are recommended by the management
of the Company and approved by the unanimous consent of those members of the
Board of Directors elected by the holders of Preferred Stock.
(b) Unless otherwise approved by the unanimous
consent of those members of the Board of Directors elected by the holders of
Preferred Stock, any such arrangements, contracts or plans with respect to the
Reserved Shares shall not provide for a vesting schedule at a rate in excess of
20% per annum from the date of issuance. Unless otherwise approved by the
unanimous consent of those members of the Board of Directors elected by the
holders of Preferred Stock, holders of the Reserved Shares shall be required to
execute Stock Restriction Agreements substantially in the form of Exhibit 2.3.
2.4 Patent, Copyright and Nondisclosure Agreement. Unless
otherwise approved by the unanimous consent of those members of the Board of
Directors elected by the holders of Preferred Stock, the Company shall require
all present and future officers, directors and technical employees of, and
consultants to, the Company and its subsidiaries to execute and deliver a
Patent, Copyright and Nondisclosure Agreement substantially in the form of
Exhibit 2.4.
2.5 Stock Restriction and Optionee Restriction
Agreements. Unless otherwise approved by the unanimous consent of those members
of the Board of Directors elected by the holders of Preferred Stock, the Company
shall cause all future purchasers of, and all future holders of options to
purchase, the Company's Common Stock who are employees or consultants of the
Company to execute and deliver a Stock Restriction Agreement or Optionee
Restriction Agreement substantially in the form of Exhibits 2.3 and 2.5,
respectively.
2.6 Termination of Company Agreements. The provisions of
Sections 2.1 through 2.5 above shall remain in full force and effect so long as
any Preferred Stock remains outstanding.
9
10
2.7 Board of Directors. Unless otherwise approved by the
holders of a majority of the outstanding shares of Preferred Stock, the Articles
shall, for so long as any shares of Preferred Stock remain outstanding, provide
for a Board of Directors of up to seven members. The Investors hereby agree (a)
not to exercise their right to vote to enlarge the Board from its current four
members to seven members prior to April 1, 1996 and (b) not to take any action,
prior to April 1, 1996, to remove or replace any of the current directors unless
holders of more than fifty percent (50%) of the outstanding shares of Preferred
Stock agree to such action.
ARTICLE III.
REGISTRATION RIGHTS
3.1 Required Registrations.
(a) If, at any time after the earlier to occur
of January 1, 2001 or six months after the effective date of the first
registration statement filed by the Company covering an offering of the
Company's securities (other than a registration relating either to the sale of
securities to employees of the Company pursuant to a stock option, stock
purchase or similar plan or a transaction under Rule 145 of the Securities Act,
or a registration on any form which does not include substantially the same
information as would be required to be included in a registration statement
covering the sale of Registrable Stock), holders of at least 40% of the
Registrable Stock then outstanding propose to dispose of at least 20% of the
Registrable Stock then outstanding or any lesser percentage if the anticipated
aggregate offering price would exceed $15,000,000, then such holders may request
the Company in writing to effect such registration, stating the form of
registration statement under the Securities Act to be used (subject to the
Company being eligible to use such registration statement), the number of shares
of Registrable Stock to be disposed of and the intended method of disposition of
such shares.
(b) If, at any time at which the Company is
eligible to file a registration statement on a Short-Form Registration
Statement, holders of Registrable Stock propose to dispose of shares of
Registrable Stock which such holders in their good faith discretion determine
would have an anticipated aggregate offering price of at least $1,000,000
pursuant to a Short-Form Registration Statement, then such holders may request
the Company in writing to effect such registration on a Short-Form Registration
Statement, stating the form of such registration statement under the Securities
Act to be used, the number of shares of Registrable Stock to be disposed of and
the intended method of disposition of such shares.
(c) Upon receipt of the request of the holders
pursuant to Section 3.1(a) or Section 3.1(b) above (in the case of Section
3.1(a) or Section 3.1(b), hereinafter referred to as the "Initiating Holders"),
the Company shall give prompt written notice thereof to all other holders of
Registrable Stock. Subject to the provisions of Section 3.2 below, the Company
shall (i) with respect to Section 3.1(a), use its best efforts promptly to
effect, and (ii) with respect to Section 3.1(b) shall promptly effect, the
registration under the Securities Act of all shares of Registrable Stock
specified in the requests of the Initiating Holders and the requests (stating
the
10
11
number of shares of Registrable Stock to be disposed of and the intended method
of disposition of such shares) of other holders of shares of Registrable Stock
("Requesting Holders") given within 30 days after receipt of such notice from
the Company.
3.2 Limitations on Required Registration.
(a) The Company shall not be required to prepare
and file more than two Long-Form Registration Statements, which actually become
or are declared effective, at the request of the Initiating Holders pursuant to
Section 3.1(a) hereof. The two required filings shall include any Long-Form
Registration Statement filed and subsequently withdrawn at the request of the
Initiating Holders unless such request is prompted by market conditions. Nothing
contained herein, however, shall limit the Company's obligation from time to
time to prepare and file a Short-Form Statement requested by the Initiating
Holders pursuant to Section 3.1(b) hereof.
(b) Only Common Stock may be included in a
registration, and, whenever a registration requested by holders of Registrable
Stock is for a firm commitment underwritten offering, if the Initiating Holders
determine that the number of shares of Common Stock so included which are to be
sold by the holders of Registrable Stock is limited due to market conditions,
the holders (including both the Initiating Holders and the Requesting Holders)
of Registrable Stock proposing to sell their shares in such underwriting and
registration shall share pro rata in the available portion of the registration
in question, such sharing to be based upon the number of shares of Registrable
Stock then held by such holders, respectively. If any holder of Registrable
Stock disapproves of the terms of the underwriting, such holder may elect to
withdraw therefrom by written notice to the Company, the underwriter and the
Initiating Holders. The Registrable Stock so withdrawn shall also be withdrawn
from registration; provided, however, that, if by the withdrawal of such
Registrable Stock, a greater number of shares of Registrable Stock held by other
holders of Registrable Stock may be included in such registration (up to the
maximum of any limitation imposed by the Initiating Holders), then the Company
shall offer to all holders of Registrable Stock who have included Registrable
Stock in the registration the right to include additional Registrable Stock in
the same proportion used in determining the limitation imposed by the provisions
of this Section 3.2(b).
(c) The Company shall not be required to prepare
and file a registration statement pursuant to Section 3.1 hereof which could
become effective within 180 days following the effective date of any
registration statement filed by the Company with the Commission pertaining to an
underwritten public offering of securities for cash for the account of the
Company if the Initiating Holders' request for registration is received by the
Company subsequent to such time as the Company in good faith gives written
notice to the holders of Registrable Stock that the Company is commencing to
prepare a Company-initiated registration statement and the Company is actively
employing in good faith all reasonable efforts to cause such registration
statement to become effective.
11
12
(d) Notwithstanding the foregoing, if the
Company shall furnish to the Initiating Holders and Requesting Holders a
certificate signed by the president of the Company stating that, in the good
faith judgment of the Board, it would be seriously detrimental to the Company
and its stockholders for such registration statement to be filed and it is
therefore essential to defer the filing of such registration statement, the
Company shall have the right to defer such filing for a period of not more than
90 days after receipt of the request of the Initiating Holders; provided,
however, that the Company may not utilize this right more than once in any
12-month period.
3.3 Incidental Registration . If the Company at any time
proposes to register any of its securities for sale for its own account or for
the account of any other Person (other than a registration relating either to
the sale of securities to employees of the Company pursuant to a stock option,
stock purchase or similar plan or a Rule 145 transaction, or a registration on
any form which does not include substantially the same information as would be
required to be included in a registration statement covering the sale of
Registrable Stock), it shall each such time give written notice (the "Company's
Notice"), at its expense, to all holders of Registrable Stock of its intention
to do so at least 45 days prior to the filing of a registration statement with
respect to such registration with the Commission. If any holder of Registrable
Stock desires to dispose of all or part of its Registrable Stock, it may request
registration thereof in connection with the Company's registration by delivering
to the Company, within 30 days after receipt of the Company's Notice, written
notice of such request (the "Investors' Notice") stating the number of shares of
Registrable Stock to be disposed of and the intended method of disposition of
such shares by such holder or holders. The Company shall use its best efforts to
cause all shares of Registrable Stock specified in the Investors' Notice to be
registered under the Securities Act so as to permit the sale or other
disposition (in accordance with the intended methods thereof as aforesaid) by
such holder or holders of the shares so registered, subject, however, to the
limitations set forth in Section 3.4 hereof.
3.4 Limitations on Incidental Registration.
(a) If the registration of which the Company
gives notice pursuant to Section 3.3 above is for the purpose of permitting a
disposition of securities by the Company pursuant to a firm commitment
underwritten offering, the notice shall so state, and the Company shall have the
right to limit the aggregate size of the offering or the number of shares to be
included therein by stockholders of the Company if requested to do so in good
faith by the managing underwriter of the offering and only securities which are
to be included in the underwriting may be included in the registration.
(b) Whenever the number of shares which may be
registered pursuant to Section 3.3 is limited by the provisions of Section
3.4(a) above, the holders of Registrable Stock shall have priority as to sales
over the other holders of the Company's securities and the Company shall cause
such other holders to withdraw from such offering to the extent necessary to
allow all requesting holders of Registrable Stock to include all of the shares
so requested to be
12
13
included within such registration. Whenever the number of shares which may be
registered pursuant to Section 3.3 is still limited by the provisions of Section
3.4(a) above, after the withdrawal of the other holders of the Company's
securities, the Company shall have priority as to sales over the holders of
Registrable Stock and each holder hereby agrees that it shall withdraw its
securities from such registration to the extent necessary to allow the Company
to include all the shares which the Company desires to sell for its own account
to be included within such registration; provided, that, except with respect to
the first Long-Form Registration Statement effected by the Company on its own
initiative, in no event shall the Registrable Stock requested to be included
pursuant to Section 3.3 above be reduced below 20% of the total amount of
securities included in such offering. The holders of Registrable Stock given
rights by Section 3.3 above shall share pro rata in the available portion of the
registration in question, such sharing to be based upon the number of shares of
Registrable Stock then held by each of such holders, respectively.
3.5 Designation of Underwriter. In the case of any
registration initiated by the Initiating Holders pursuant to the provisions of
Section 3.1 hereof which is proposed to be effected pursuant to a firm
commitment underwriting and, subject to the approval of the Company, which
approval shall not be unreasonably withheld, the Initiating Holders shall have
the right to designate the managing underwriter, and all holders of Registrable
Stock participating in the registration shall sell their shares only pursuant to
such underwriting.
3.6 Registration Procedures.
(a) If and when the Company is required by the
provisions of this Agreement to use its best efforts to effect the registration
of shares of Registrable Stock, the Company shall:
(i) prepare and file with the
Commission a registration statement (the form and substance of which shall be
subject to the approval of the holders of a majority of the Registrable Stock to
be included in such registration) with respect to such shares and use its best
efforts to cause such registration statement to become and remain effective for
a period described in Section 3.15 hereof;
(ii) prepare and file with the
Commission such amendments and supplements to such registration statement and
the prospectuses used in connection therewith as may be necessary to keep such
registration statement effective and current and to comply with the provisions
of the Securities Act with respect to the sale or other disposition of all
shares covered by such registration statement, including such amendments and
supplements as may be necessary to reflect the intended method of disposition
from time to time of the holder or holders of Registrable Stock who have
requested that any of their shares be sold or otherwise disposed of in
connection with the registration (the "Prospective Sellers");
13
14
(iii) furnish to each Prospective Seller
such number of copies of each prospectus, including preliminary prospectuses, in
conformity with the requirements of the Securities Act, and such other
documents, as the Prospective Seller may reasonably request in order to
facilitate the public sale or other disposition of the shares owned by it;
(iv) use its best efforts to register or
qualify the shares covered by such registration statement under such other
securities or blue sky or other applicable laws of such jurisdictions as each
Prospective Seller shall reasonably request to enable such seller to consummate
the public sale or other disposition of the shares owned by such seller,
provided that the Company shall not be required in connection therewith or as an
election thereto to qualify to do business or to file a general consent to
service of process in any such jurisdiction;
(v) upon written request, furnish to
each Prospective Seller a signed counterpart, addressed to the Prospective
Sellers and their underwriters, if any, of: (A) an opinion of counsel for the
Company, dated the effective date of the registration statement; and (B) a
"comfort" letter signed by the independent public accountants who have certified
the Company's financial statements included in the registration statement;
covering substantially the same matters with respect to the registration
statement (and the prospectus included therein) and (in the case of the
accountants' letter) with respect to the events subsequent to the date of the
financial statements, as are customarily covered (at the time of such
registration) in the opinions of issuers' counsel and in accountants' letters
delivered to the underwriters in connection with underwritten public offerings
of securities;
(vi) cause all such Registrable Stock to
be listed on each securities exchange or other securities trading market on
which similar securities issued by the Company are then listed;
(vii) provide a transfer agent and
registrar for all such Registrable Stock not later than the effective date of
such registration statement;
(viii) enter into such customary
agreements (including an underwriting agreement) and take all such other
customary actions as the holders of a majority of the Registrable Stock being
sold reasonably request in order to expedite or facilitate the disposition of
such Registrable Stock; and
(ix) make available for inspection by
any Prospective Seller, any underwriter participating in any disposition
pursuant to such registration statement, and any attorney, accountant or other
agent retained by any such seller or underwriter, all financial and other
records, pertinent corporate documents and properties of the Company, and cause
the Company's officers, directors and employees to supply all information
reasonably requested by any such seller, underwriter, attorney, accountant or
agent in connection with the preparation of such registration statement.
14
15
(b) Each Prospective Seller of Registrable
Stock, shall furnish to the Company such information as the Company may
reasonably require from the Prospective Seller for inclusion in the registration
statement (and the prospectus included therein).
(c) The Prospective Sellers shall not (until
further notice) effect sales of the shares covered by the registration statement
after receipt of telegraphic or written notice from the Company to suspend sales
to permit the Company to correct or update a registration statement or
prospectus.
3.7 Expenses of Registration.
(a) All expenses incurred in effecting any
registration requested pursuant to Section 3.1 or 3.3 hereof, including, without
limitation, all registration and filing fees, printing expenses, expenses of
compliance with blue sky laws, fees and disbursements of counsel for the
Company, fees and disbursements of one counsel for the holders of Registrable
Stock selected by the holders of a majority of the Registrable Stock so to be
offered for sale and reasonably acceptable to the Company, expenses of any
audits incidental to or required by any such registration, and reasonable
expenses of all marketing and promotional efforts requested by the managing
underwriter shall be borne by the Company; provided, however, that each
Prospective Seller shall bear its own underwriting discounts or brokerage fees
or commissions relating to the sale of its Registrable Stock.
3.8 Indemnification.
(a) In the event of any registration of any of
its securities under the Securities Act pursuant to this Agreement, the Company
shall indemnify and hold harmless each Investor requesting or joining in a
registration of such securities, each underwriter (as defined in the Securities
Act), each officer, director and partner of any Investor or underwriter and each
controlling person of any Investor or underwriter, if any (within the meaning of
the Securities Act), against any expenses, losses, claims, damages or
liabilities, joint or several (or actions in respect thereof), to which such
Investor, underwriter, officer, director, partner or controlling person may be
subject under the Securities Act, under any other statute or at common law,
insofar as such expenses, losses, claims, damages or liabilities (or actions in
respect thereof), including any of the foregoing incurred in settlement of any
litigation, commenced or threatened, arising out of or are based upon (i) any
untrue statement (or alleged untrue statement) of any material fact contained in
any registration statement under which such securities were registered under the
Securities Act, any preliminary prospectus or final prospectus contained
therein, or any summary prospectus issued in connection with any securities
being registered or any other document, or any amendment or supplement thereto,
or any omission (or alleged omission) to state therein a material fact required
to be stated therein or necessary to make the statements therein not misleading,
in light of the circumstances in which they were made or (ii) any violation by
the Company of the Securities Act or any blue sky law, or any rule or regulation
promulgated under the Securities Act or any blue sky law, or any other law,
applicable to the Company in connection
15
16
with any such registration, qualification or compliance of any shares of
Registrable Stock, and shall reimburse each such Investor, underwriter, officer,
director, partner or controlling person for any legal or other expenses
reasonably incurred by such Investor, underwriter, officer, director, partner or
controlling person in connection with investigating, preparing or defending any
such expense, loss, claim, damage, liability or action; provided, however, that
the Company shall not be liable to any Investor, underwriter, officer, director,
partner or controlling person in any such case to the extent that any such loss,
claim, damage or liability arises out of or is based upon any such untrue
statement or omission made in such registration statement, preliminary
prospectus, summary prospectus, final prospectus or any other document, or
amendment or supplement thereto in reliance upon and in conformity with written
information furnished to the Company by such Investor, underwriter, officer,
director, partner or controlling person, respectively, specifically for use
therein. The indemnity provided for herein shall remain in full force and effect
regardless of any investigation made by or on behalf of such Investor,
underwriter, officer, director, partner or controlling person, and shall survive
the transfer of such securities by such Investor.
(b) The Company may require, as a condition to
including any Registrable Stock of a Prospective Seller in any registration
statement filed pursuant to Section 3.1 or Section 3.3, that the Company shall
have received an undertaking satisfactory to it from such Prospective Seller,
severally and not jointly, to indemnify and hold harmless (in the same manner
and to the same extent as set forth in Section 3.8(a)) the Company, each
director of the Company, each officer of the Company who shall sign such
registration statement and each other person, if any, who controls the Company
within the meaning of the Securities Act (except the indemnifying Investor, if
such indemnifying Investor so controls the Company), with respect to (i) any
untrue statement (or alleged untrue statement) of any material fact contained in
any registration statement under which such securities were registered under the
Securities Act, any preliminary prospectus or final prospectus contained
therein, or any summary prospectus issued in connection with any securities
being registered or any other document, or any amendment or supplement thereto,
or any omission (or alleged omission) to state therein a material fact required
to be stated therein or necessary to make the statements therein not misleading,
in light of the circumstances in which they were made or (ii) any violation by
the Prospective Investor of the Securities Act or any blue sky law, or any rule
or regulation promulgated under the Securities Act or any blue sky law, or any
other law, applicable to the Company in connection with any such registration,
qualification or compliance of any shares of Registrable Stock, in each case if
such statement or omission was made in reliance on and in conformity with
written information furnished to the Company by such Prospective Seller
specifically for use in preparing any such registration statement, preliminary
prospectus, final prospectus, summary prospectus or amendment or supplement
thereto, or in making any such filing or representation. Each Prospective Seller
hereunder shall promptly provide such indemnification upon request. The
indemnity provided for herein shall remain in full force and effect regardless
of any investigation made by or on behalf of the indemnified party and shall
survive any transfer of the Registrable Stock held by the indemnifying party. In
no event shall a Prospective Seller's obligation to
16
17
indemnify any Person hereunder exceed the net proceeds from the sale of the
Prospective Seller's Registrable Stock in the offering.
(c) If the indemnification provided for in Section 3.8(a)
or Section 3.8(b) above is held by a court of competent jurisdiction to be
unavailable to an indemnified party in respect of any expenses, losses, claims,
damages or liabilities referred to therein, then the indemnifying party, in lieu
of indemnifying such indemnified party thereunder, shall contribute to the
amount paid or payable by such indemnified party as a result of such expenses,
losses, claims, damages or liabilities, in such proportion as is appropriate to
reflect the relative fault of the indemnifying party on the one hand and of the
indemnified parties on the other in connection with the statements or omissions
or violations which resulted in such expenses, losses, claims, damages or
liabilities, as well as any other relevant equitable considerations. The
relative fault of the indemnifying party and of the indemnified parties shall be
determined by reference to, among other things, whether the untrue or alleged
untrue statement of a material fact or the omission to state a material fact
relates to information supplied by the indemnifying party or by the indemnified
parties, and the parties' relative intent, knowledge, access to information and
opportunity to correct or prevent such statement or omission.
The Company and the Investors agree that it would not be just
and equitable if contribution pursuant to this Section 3.8(c) were determined by
pro rata allocation or by any other method of allocation which does not take
into account the equitable considerations referred to in the immediately
preceding paragraph. The amount paid or payable by an indemnified party as a
result of the losses, claims, damages and liabilities or actions in respect
thereof referred to in the immediately preceding paragraph shall be deemed to
include, subject to the limitations set forth above, any legal or other expenses
reasonably incurred by such indemnified party in connection with investigating
or defending any such action or claim. Notwithstanding the provisions of this
Section 3.8(c), no Prospective Seller shall be required to contribute any amount
in excess of the net proceeds from the sale of the Prospective Seller's
Registrable Stock in the Offering. No person guilty of fraudulent
misrepresentations (within the meaning of Section 11(f) of the Securities Act)
shall be entitled to contribution from any person who was not guilty of such
fraudulent misrepresentation. The Company may require, as a condition to
including any Registrable Stock of a Prospective Seller in any registration
statement filed pursuant to Section 3.1 or Section 3.3, that the Company shall
have received an undertaking satisfactory to it from such Prospective Seller of
such Registrable Stock, severally and not jointly, to contribute to the amount
paid or payable by an indemnified party hereunder as and to the extent set forth
in this Section 3.8(c), and each Investor hereunder shall promptly provide such
undertaking upon request.
(d) Promptly after receipt by an indemnified party under
Section 3.8(a) or Section 3.8(b) above of notice of the commencement of any
action, such indemnified party shall, if a claim in respect thereof is to be
made under such Section, notify the indemnifying party in writing of the
commencement thereof; but the omission so to notify the indemnifying party shall
not relieve it from any liability which it may have to any indemnified party
otherwise than under
17
18
such Section or to the extent that it has not been prejudiced as a proximate
result of such failure. In case any such action shall be brought against any
indemnified party, and it shall notify the indemnifying party of the
commencement thereof, the indemnifying party shall be entitled to participate
therein and, to the extent that it shall wish, to assume the defense thereof,
with counsel satisfactory to such indemnified party; provided, however, that, if
the defendants in any such action include both the indemnified party and the
indemnifying party and the indemnified party shall have reasonably concluded
that there may be legal defenses available to it and/or other indemnified
parties which are different from or additional to those available to the
indemnifying party, the indemnified party or parties shall have the right to
select separate counsel to assert such legal defenses (in which case the
indemnifying party shall not have the right to direct the defense of such action
on behalf of the indemnified party or parties). Upon the permitted assumption by
the indemnifying party of the defense of such action, and approval by the
indemnified party of counsel, the indemnifying party shall not be liable to such
indemnified party under this Section 3.8 for any legal or other expenses
subsequently incurred by such indemnified party in connection with the defense
thereof (other than reasonable costs of investigation) unless (i) the
indemnified party shall have employed separate counsel in connection with the
assertion of legal defenses in accordance with the proviso to the next preceding
sentence, (ii) the indemnifying party shall not have employed counsel
satisfactory to the indemnified party to represent the indemnified party within
a reasonable time, (iii) the indemnified party and its counsel do not actively
and vigorously pursue the defense of such action, or (iv) the indemnifying party
has authorized the employment of counsel for the indemnified party at the
expense of the indemnifying party.
3.9 Inclusion of Additional Shares in Required
Registrations; Other Company Initiated Registrations. The Company shall not
register securities for sale for its own account or for the account of any other
Person in any registration requested by the holders of Registrable Stock
pursuant to Section 3.1 hereof unless permitted to do so by the written consent
of the holders of at least 51% of the Registrable Stock as to which registration
has been requested. The Company may not cause any other registration of
securities for sale for its own account or for the account of any other Person
to become effective within 180 days after the effective date of any registration
requested by the holders of Registrable Stock pursuant to Section 3.1 hereof
except pursuant to registrations on Form S-8 or Form S-4 or any successors
thereto.
3.10 Rights Which May Be Granted to Other Persons. The
Company shall not grant any Person registration rights which shall in any way
whatsoever impair the priority of the registration rights granted to the
Investors in this Agreement; provided, that the Company may grant to Phoenix
Growth Capital Corporation ("Phoenix") registration rights which are on parity
with the registration rights granted to the Investors herein and may, in
connection therewith, require Phoenix to become a party to this Agreement.
3.11 Rule 144 Requirements. Immediately after the date on
which a registration statement filed by the Company under the Securities Act
becomes effective, the Company shall undertake to make publicly available, and
available to the holders of Registrable Stock, such information as is necessary
to enable the holders of Registrable Stock to make sales of Registrable
18
19
Stock pursuant to Rule 144 of the Commission under the Securities Act. The
Company shall furnish to any holder of Registrable Stock, upon request, a
written statement executed by the Company as to the steps it has taken to comply
with the current public information requirements of Rule 144.
3.12 Sale of Preferred Stock to Underwriter.
Notwithstanding any provision of this Agreement to the contrary, in lieu of
converting any shares of Preferred Stock prior to the filing of any registration
statement filed pursuant to this Agreement, the holder of such shares may sell
such shares of Preferred Stock to the underwriters of the offering being
registered upon the undertaking of such underwriters to convert the Preferred
Stock on or prior to the closing date of the offering. The Company agrees to
cause the Common Stock issuable on the conversion of the Preferred Stock to be
issued within such time period as will permit the underwriters to make and
complete the distribution contemplated by the underwriting.
3.13 Holdback. If the Company files a registration
statement in connection with an underwritten public offering, a holder of
Registrable Stock, if so requested by the managing underwriter of such public
offering, shall not effect any sale or distribution of any shares (except
pursuant to such registration statement) of the capital stock of the Company,
whether now owned or hereafter acquired, during the period commencing with the
effective date of such registration statement and ending on the close of
business on the 120th day thereafter or such time as the registration statement
is withdrawn, whichever is earlier.
3.14 Transfer of Registration Rights. The registration
rights of any Investor under this Agreement may be transferred only to (i) any
transferee who acquires at least twenty percent (20%) of such Investor's
Registrable Stock, or (ii) a Permitted Transferee.
3.15 Effective Period of Registration. Once any
registration effected by the Company pursuant to this Article III becomes
effective, the Company shall file all reports, financial statements and other
documents necessary to keep such registration statement current and the
registration in effect until the earlier of (i) the sale of all securities
offered for sale pursuant to the registration statement, or (ii) three months
from the effective date of the registration statement.
ARTICLE IV.
RESTRICTIONS ON TRANSFER
4.1 Notice. If an Investor desires to offer, sell,
assign, pledge, transfer or dispose of its Preferred Stock or Registrable Stock
(the "Offered Shares") to a Person in a transaction other than to a Permitted
Transferee, pursuant to Sections 3.1 or 3.3 hereof, or pursuant to Rule 144
under the Securities Act, such Investor (the "Offeror") shall notify (the "Sale
Notice") the other Investors (the "Nonoffering Investors") and the Company in
writing of the (a) proposed price (the "Price") and terms of payment (the
"Terms") for all Offered Shares
19
20
owned by the Offeror that the Offeror seeks for its Offered Shares, and (b)
class and the percentage of the total number of shares of that class and of all
Preferred Stock and Registrable Stock then held by such Investor represented by
the Offered Shares. The Sale Notice shall constitute an offer by the Offeror to
the Nonoffering Investors and to the Company to sell all Offered Shares owned by
the Offeror to the Nonoffering Investors and to the Company at the Price and on
the Terms.
4.2 Nonoffering Investors' Exercise of Right of First
Refusal. Each Nonoffering Investor shall have the right to purchase, at the
Price and payable in accordance with the Terms, that proportion of the Offered
Shares equal to an amount which the number of shares of Preferred Stock and
Registrable Stock then owned of record by such Nonoffering Investor bears to the
total number of shares of Preferred Stock and Registrable Stock then owned of
record by all Investors other than the Offeror. The Nonoffering Investors may
exercise their rights by giving written notice to the Offeror within 30 days
after the date of receipt of the Sale Notice.
In the event any Nonoffering Investor does not elect to
purchase any or all of the Offered Shares under this Section 4.2 (the
"Unpurchased Offered Shares"), then the other Nonoffering Investors so electing
to purchase the Offered Shares shall have the right to elect to purchase that
proportion of the Unpurchased Offered Shares equal to an amount which the number
of Offered Shares originally requested to be purchased by such Nonoffering
Investor bears to the total number of Offered Shares originally requested to be
purchased by all Nonoffering Investors. Any Nonoffering Investor electing to
purchase the Offered Shares (a "Purchasing Investor") shall give written notice
to the Offeror, the other Investors and the Company of such election to purchase
the Offered Shares (and the maximum number of Offered Shares that such Investor
is willing to purchase) within the 30-day period specified in this Section 4.2.
4.3 Company's Exercise of Right of First Refusal. In the
event the Nonoffering Investors do not elect to purchase all of the Offered
Shares pursuant to Section 4.2 hereof, then the Company shall have the right to
purchase any remaining Unpurchased Offered Shares at the Price and payable in
accordance with the Terms. The Company may exercise its right by giving written
notice to the Offeror within 30 days after the expiration of the 30-day period
specified in Section 4.2 hereof. The Offeror shall not participate in the
determination by the Company on whether to exercise the right provided in this
Section 4.3. If the Company does not exercise its right or does not purchase all
of the remaining Unpurchased Offered Shares at the Price and in accordance with
the Terms, it shall notify the Offeror and the Purchasing Investors that it is
not doing so within such 30-day period. Unless otherwise agreed by the Offeror,
all the Offered Shares must be purchased by the Nonoffering Investors and the
Company pursuant to Section 4.2 and this Section 4.3, respectively, or none may
be so purchased.
4.4 Closing. The consummation of the purchase by the
Purchasing Investors and the Company pursuant to any exercise of the rights set
forth above shall occur at a closing (the "Closing") to be held at the principal
offices of the Company not later than 75 days following the date on which the
Nonoffering Investors and the Company received the Sale Notice described
20
21
in Section 4.1. At the Closing, the Purchasing Investors and the Company, as
appropriate, shall make payment for the Offered Shares in accordance with the
Terms, and the Offeror shall deliver the Offered Shares, duly endorsed for
transfer, to the Purchasing Investors and the Company, as appropriate, with all
required revenue stamps attached.
4.5 Transfer to Third Party. If the rights provided above
are not exercised as to all of the Offered Shares (unless otherwise agreed to by
the Offeror), or if the purchase by the Nonoffering Investors and the Company is
not consummated within the time specified in Section 4.4 through no fault of the
Offeror, then the Offeror may transfer all, but not less than all, of the
Offered Shares not so purchased to any third party at not less than the Price
and payable in accordance with the Terms or on such other terms as the Board, in
its sole discretion, determines in good faith would not have been accepted by
the Nonoffering Investors and the Company if such terms had been offered to the
Nonoffering Investors and the Company. If the transfer by the Offeror of the
Offered Shares to a third party is not consummated within 150 days after the
date the Offeror first becomes free to make such transfer, the right to transfer
in accordance with this Article IV shall expire. In such event, the restrictions
of this Agreement shall be reinstated as to the Offered Shares and any transfer
of such Offered Shares proposed to be made by the Offeror subsequent to the
expiration of that 150-day period must be made in accordance with this
Agreement.
ARTICLE V.
MISCELLANEOUS
5.1 Adjustments Affecting Registrable Securities. The
Company shall not effect a stock split or combination of shares or take any
other action, or permit any change to occur, with respect to its Equity
Securities that would adversely affect at such time the ability of the holders
of Registrable Stock to include such Registrable Stock in a registration
undertaken pursuant to this Agreement or which would adversely affect the
marketability of such Registrable Stock in any such registration.
5.2 Notices. All notices, demands or other communications
hereunder shall be in writing and shall be deemed given when delivered
personally, mailed by certified mail (return receipt requested), sent by
overnight courier service or telecopied (transmission confirmed), or otherwise
actually delivered:
21
22
If to Investors: Alliance Technology Ventures, Limited Partnership
ATV/GP Parallel Fund, Limited Partnership
ATV/MFJ Parallel Fund, Limited Partnership
000 Xxxxxxxxx Xxxxxx Xxxxxx, Xxxxx 0000
Xxxxxxx, Xxxxxxx 00000
Attention: Xxxxxxx X. Xxxxx
Telephone: (000) 000-0000
Facsimile: (000) 000-0000
Intelligent Systems Corporation
0000 Xxxxxxxxxxx Xxxx
Xxxxxxxx, Xxxxxxx 00000
Attention: Xxxxxx Xxxxxxx
Telephone: (000) 000-0000
Facsimile: (000) 000-0000
International Murex Technologies Corporation
0000 Xxxxxxxxxx Xxxxxx
Xxxxxxxx, Xxxxxxx 00000
Attention: President
Attention: Secretary
Telephone: (000) 000-0000
Facsimile: (000) 000-0000
Sanderling III Limited
Sanderling Venture Partners III
Sanderling III Biomedical
Sanderling Venture Management
0000 Xxxx Xxxx Xxxx
Xxxxx 000
Xxxxx Xxxx, Xxxxxxxxxx 00000-0000
Attention: Xxxxxx XxXxxx
Telephone: (000) 000-0000
Facsimile: (000) 000-0000
New York Life Insurance Company
00 Xxxxxxx Xxxxxx
Xxx Xxxx, Xxx Xxxx 00000
Attention: Xxxxxxxxx Xxxxx
Telephone: (000) 000-0000
Facsimile: (000) 000-0000
22
23
If to Company: AtheroGenics, Inc.
0000 Xxxxxxxxxx Xxxxxx
Xxxxxxxx, Xxxxxxx 00000
Attention: R. Xxxxx Xxxxxxxxx
Telephone: (000) 000-0000
Facsimile: (000) 000-0000
If to any other Investor: At the address and numbers set forth in the
Company's records, marked for attention as
therein indicated;
or at such other address and numbers as may have been furnished by such person
in writing to the other parties.
5.3 Severability and Governing Law. Should any Section or
any part of a Section within this Agreement be rendered void, invalid or
unenforceable by any court of law for any reason, such invalidity or
unenforceability shall not void or render invalid or unenforceable any other
Section or part of a Section in this Agreement. This Agreement is made and
entered into in the State of Georgia and the laws of said state shall govern the
validity and interpretation hereof and the performance by the parties hereto of
their respective duties and obligations hereunder.
5.4 Counterparts. This Agreement may be executed in
multiple counterparts, each of which shall be deemed an original but all of
which together shall constitute one and the same instrument.
5.5 Captions and Section Headlines. Section titles or
captions contained in this Agreement are inserted as a matter of convenience and
for reference purposes only, and in no way define, limit, extend or describe the
scope of this Agreement or the intent of any provision hereof.
5.6 Singular and Plural, Etc. Whenever the singular
number is used herein and where required by the context, the same shall include
the plural, and the neuter gender shall include the masculine and feminine
genders.
5.7 Costs and Attorneys' Fees. In the event that any
action, suit or other proceeding is instituted concerning or arising out of this
Agreement, the prevailing party shall recover all of such party's costs, and
attorneys' fees incurred in each and every such action, suit or other
proceeding, including any and all appeals or petitions therefrom. As used
herein, "attorneys' fees" shall mean the full and actual costs of any legal
services actually rendered in connection with the matters involved, calculated
on the basis of the usual fee charged by the attorneys performing such services.
23
24
5.8 Amendments and Waivers. Neither this Agreement nor
any term hereof may be changed, waived, discharged or terminated orally or in
writing, except that any term of this Agreement may be amended and the
observance of any such term may be waived (either generally or in a particular
instance and either retroactively or prospectively) only with the written
consent of the Company and the holders of at least 66-2/3% of the Registrable
Stock then in existence; provided, however, that no such amendment or waiver
shall affect the provisions of this Section 5.8 and no such waiver shall extend
to or affect any other obligation not expressly waived. No failure to exercise
and no delay in exercising, on the part of any party, any right, remedy, power
or privilege hereunder shall operate as a waiver thereof; nor shall any single
or partial exercise of any right, remedy, power or privilege hereunder preclude
any other or further exercise thereof or the exercise of any other right remedy,
power or privilege. The rights, remedies, powers and privileges herein provided
are cumulative and not exclusive of any rights, remedies, powers and privileges
provided by law. The failure of any party to insist upon a strict performance of
any of the terms or provisions of this Agreement, or to exercise any option,
right or remedy herein contained, shall not be construed as a waiver or as a
relinquishment for the future of such term, provision, option, right or remedy,
but the same shall continue and remain in full force and effect.
5.9 Successors and Assigns. All rights, covenants and
agreements of the parties contained in this Agreement shall, except as otherwise
provided herein, be binding upon and inure to the benefit of their respective
successors and assigns.
5.10 Specific Performance. The parties hereto agree that
the capital stock of the Company cannot be purchased or sold in the open market
and that, for these reasons, among others, the parties will be irreparably
damaged in the event that this Agreement is not specifically enforceable.
Accordingly, in the event of any controversy concerning the capital stock which
is the subject of this Agreement, or any right or obligation to register such
securities, such right or obligation shall be enforceable in a court of equity
by specific performance. The rights granted in this Section 5.10 shall be
cumulative and not exclusive, and shall be in addition to any and all other
rights which the parties hereto may have hereunder, at law or in equity.
5.11 Entire Agreement. This Agreement contains the entire
understanding of the parties and there are no further or other agreements or
understandings, written or oral, in effect between the parties relating to the
subject matter hereof unless expressly referred to herein. Without limiting the
foregoing, this Agreement specifically supersedes that certain Master Rights
Agreement dated May 6, 1994 between the Company and Alliance.
5.12 No Third-Party Beneficiaries. With the exception of
the parties to this Agreement and the holders of Common Stock afforded the
limited registration rights described herein, there shall exist no right of any
Person to claim a beneficial interest in this Agreement, or any rights accruing
by virtue of this Agreement.
24
25
IN WITNESS WHEREOF, the parties hereto have executed and
delivered this Master Rights Agreement by duly authorized officers as of the
date first above written.
ATHEROGENICS, INC.
By: /s/ Xxxxxxx X. Xxxxxxx
------------------------------------------
Name: Xxxxxxx X. Xxxxxxx
----------------------------------------
Title: Exec. Vice President Secretary
---------------------------------------
ALLIANCE TECHNOLOGY VENTURES,
LIMITED PARTNERSHIP
By: /s/ Xxxxxxx X. Xxxxx
------------------------------------------
Name: Xxxxxxx X. Xxxxx
----------------------------------------
Title: General Partner
---------------------------------------
ATV/GP PARALLEL FUND, LIMITED
PARTNERSHIP
By: /s/ Xxxxxxx X. Xxxxx
------------------------------------------
Name: Xxxxxxx X. Xxxxx
----------------------------------------
Title: General Partner
---------------------------------------
ATV/MFJ PARALLEL FUND, LIMITED
PARTNERSHIP
By: /s/ Xxxxxxx X. Xxxxx
------------------------------------------
Name: General Partner
----------------------------------------
Title:
---------------------------------------
INTELLIGENT SYSTEMS CORPORATION
By: /s Xxxxxx Xxxxxx
------------------------------------------
Name: Xxxxxx Xxxxxx
----------------------------------------
Title: V.P..
---------------------------------------
X-0
00
XXXXXXXXXXXXX XXXXX TECHNOLOGIES
CORP.
By: /s/ J. Xxxxx Xxxxxx
------------------------------------------
Name: J. Xxxxx Xxxxxx
----------------------------------------
Title: President & CEO, COO
---------------------------------------
SANDERLING III LIMITED
By: /s/ Xxxxxx X. XxXxxx
------------------------------------------
Name: Xxxxxx X. XxXxxx
----------------------------------------
Title: General Partner
---------------------------------------
SANDERLING VENTURE PARTNERS III
By: /s/ Xxxxxx X. XxXxxx
------------------------------------------
Name: Xxxxxx X. XxXxxx
----------------------------------------
Title: General Partner
---------------------------------------
SANDERLING III BIOMEDICAL
By: /s/ Xxxxxx X. XxXxxx
------------------------------------------
Name: Xxxxxx X. XxXxxx
----------------------------------------
Title: General Partner
---------------------------------------
SANDERLING VENTURES MANAGEMENT
By: /s/ Xxxxxx X. XxXxxx
------------------------------------------
Name: Xxxxxx X. XxXxxx
----------------------------------------
Title: General Partner
---------------------------------------
S-2
27
FIRST AMENDMENT TO AMENDED AND RESTATED
MASTER RIGHTS AGREEMENT
THIS FIRST AMENDMENT TO AMENDED AND RESTATED MASTER RIGHTS AGREEMENT
(the "Amendment"), dated as of November 1, 1995, is entered into by and among
ATHEROGENICS, INC., a Georgia corporation (the "Company"), and the other parties
hereto, with respect to the Amended and Restated Master Rights Agreement, dated
as of October 31, 1995, by and among the Company and the other parties thereto
(the "Agreement").
RECITALS
WHEREAS, the Company proposes to issue a Warrant (the "Phoenix
Warrant") to Phoenix Leasing Incorporated ("Phoenix") to acquire shares of the
Company's Series B Convertible Preferred Stock (the shares acquirable under the
Phoenix Warrant hereafter the "Warrant Shares");
WHEREAS, under the terms of the Phoenix Warrant, the Company must grant
to Phoenix with respect to the Warrant Shares the same registration rights as
granted to the Investors, as defined in the Agreement;
WHEREAS, to grant Phoenix registration rights in its capacity as the
holder of the Phoenix Warrant would require certain amendments to the Agreement;
WHEREAS, under Section 5.8 of the Agreement, the Agreement may be
amended only with the written consent of the holders of at least 66-2/3% of the
Registrable Stock, as defined in the Agreement, then in existence; and
WHEREAS, in order to grant Phoenix the rights required under the
Phoenix Warrant, the parties hereto desire to enter into this Amendment in
accordance with Section 5.8 of the Agreement;
NOW, THEREFORE, IT IS AGREED THAT:
1. Definitions. All capitalized terms used herein without definition
shall have the meanings ascribed to them in the Agreement.
2. Amendments. The Agreement is hereby amended as follows:
(a) Section 1.1(l) is amended to read as follows:
1
28
(1) "Investors." The term "Investors" shall mean
Alliance, ATV/GP, ATV/MFJ, Intelligent Systems, Murex,
Sanderling Limited, Sanderling Venture, Sanderling Biomedical,
Sanderling Management, NY Life and Phoenix Leasing
Incorporated, their respective successors and assigns and any
other holder of Preferred Stock who by amendment is added as a
party to this Agreement.
(b) Section 2.2(c)(vi) is amended to read as follows:
(vi) the issuance is pursuant to the Warrant, dated
November 1, 1995, issued to Phoenix Leasing Incorporated.
3. Phoenix. Upon the effectiveness of this Amendment, as provided
in Section 4 hereof, Phoenix Leasing Incorporated agrees to be bound by all of
the terms and conditions of the Agreement applicable to Investors.
4. Effectiveness. This Amendment shall become effective upon the
execution hereof by (a) the Company, and (b) the holders 66-2/3% of the
Registrable Stock.
5. Effect of Amendment. Except as amended as set forth above, the
Agreement shall continue in full force and effect.
6. Counterparts. This Amendment may be signed in one or more
counterparts, each of which shall be deemed an original and all of which, taken
together, shall be deemed one and the same documents.
2
29
IN WITNESS WHEREOF, the parties hereto have executed this Amendment as
of the day and year first above written.
ATHEROGENICS, INC.
By: /s/ Xxxxxxx X. Xxxxxxx, MD, PhD
-------------------------------------
Name: Xxxxxxx X. Xxxxxxx, MD, PhD
-----------------------------------
Title: President and C.E.O.
----------------------------------
ALLIANCE TECHNOLOGY VENTURES, L.P.
ATV/GP PARALLEL FUND, L.P.
ATV/MFJ PARALLEL FUND, L.P.
By: /s/ Xxxxxxx X. Xxxxx
-------------------------------------
Name: Xxxxxxx X. Xxxxx
-----------------------------------
Title: General Partner
----------------------------------
INTELLIGENT SYSTEMS CORPORATION
By: /s/ J. Xxxxxx Xxxxxxx
-------------------------------------
Name: J. Xxxxxx Xxxxxxx
-----------------------------------
Title: President
----------------------------------
INTERNATIONAL MUREX TECHNOLOGIES
CORPORATION
By: /s/ J. Xxxxx Xxxxxx
-------------------------------------
Name: J. Xxxxx Xxxxxx
-----------------------------------
Title: President/CEO
----------------------------------
NEW YORK LIFE INSURANCE COMPANY
By: /s/ Xxxxxxxxx X. Xxxxx
-------------------------------------
Name: Xxxxxxxxx X. Xxxxx
-----------------------------------
Title: Assistant Vice President
----------------------------------
30
SANDERLING III LIMITED PARTNERSHIP
SANDERLING VENTURE PARTNERS III, L.P.
SANDERLING III BIOMEDICAL, L.P.
SANDERLING VENTURES MANAGEMENT
By: /s/ Xxxxxx X. XxXxxx
-------------------------------------
Name: Xxxxxx X. XxXxxx
-----------------------------------
Title: General Partner
----------------------------------
PHOENIX LEASING INCORPORATED
By: /s/ N. H. Xxxxxx
-------------------------------------
Name: N. H. Xxxxxx
-----------------------------------
Title: Vice President
----------------------------------
2
31
SECOND AMENDMENT TO AMENDED AND RESTATED
MASTER RIGHTS AGREEMENT
THIS SECOND AMENDMENT TO AMENDED AND RESTATED MASTER RIGHTS AGREEMENT
(the "Amendment"), dated as of July 30, 1996, is entered into by and among
ATHEROGENICS, INC., a Georgia corporation (the "Company"), and the other parties
listed on the signature page hereto, with respect to the Amended and Restated
Master Rights Agreement, dated as of October 31, 1995, by and among the Company
and the other parties thereto, as amended (the "Agreement").
RECITALS
WHEREAS, the Company intends to sell additional shares of its Series B
Convertible Preferred Stock (the "Series B Preferred") to certain purchasers
(the "Purchasers") pursuant to the terms of a Series B Convertible Preferred
Stock Purchase Agreement of even date herewith (the "Purchase Agreement"); and
WHEREAS, pursuant to the terms of the Purchase Agreement, the
Purchasers who are not already holders of Registrable Stock (as defined in the
Agreement) (the "New Purchasers") must be added as parties to the Agreement; and
WHEREAS, to add the New Purchasers as parties to the Agreement would
require certain amendments to the Agreement; and
WHEREAS, pursuant to Section 5.8 of the Agreement, the Agreement may be
amended only with the written consent of the Company and the holders of at least
66-2/3% of the Registrable Stock then in existence; and
WHEREAS, in order to add the New Purchasers as parties to the Agreement
and to make certain other amendments to the Agreement, the parties hereto desire
to enter into this Amendment in accordance with Section 5.8 of the Agreement;
NOW, THEREFORE, IT IS AGREED THAT:
1. Definitions. All capitalized terms used herein without
definition shall have the meanings ascribed to them in the Agreement.
2. Amendments. The Agreement is hereby amended as follows:
(a) Section 1.1(l) is amended to read as follows:
32
(1) "Investors." The term "Investors" shall mean
Alliance, ATV/GP, ATV/MFJ, Intelligent Systems, Murex,
Sanderling Limited, Sanderling Venture, Sanderling Biomedical,
Sanderling Management, NY Life , Phoenix Leasing Incorporated,
Sprout Capital VII, L.P., Sprout CEO Fund, L.P., DLJ Capital
Corp., DLJ First ESC L.L.C., DP III Associates, L.P., Old
Court Limited, Domain Partners III, L.P., Xxx X. Xxxxxx,
Xxxxxx X. Xxxxxx, Xxx X. Xxxx, Xxxxxx X. Xxxxxx, their
respective successors and assigns and any other holder of
Preferred Stock who by amendment is added as a party to this
Agreement.
(b) Section 2.2(c)(ii) is hereby amended by deleting
therefrom the number "800,000" and replacing it with the number
"2,038,500".
(c) Section 2.2(c) is hereby amended by adding a new
subparagraph (x) to that section which shall be and read in its
entirety as follows:
"(x) the issuance is of additional shares of Series B
Convertible Preferred Stock at a price per share of
not less than $3.00, provided, that the total of all
such shares does not exceed 3,053,334 shares."
3. New Purchasers. Upon the effectiveness of this Amendment, as
provided in Section 4 hereof, the New Purchasers shall have all of the rights
and privileges and shall be bound by all of the terms and conditions of the
Agreement applicable to Investors.
4. Effectiveness. This Amendment shall become effective upon the
execution hereof by (a) the Company, (b) the holders of 66-2/3% of the
Registrable Stock outstanding immediately prior to the issuance of shares of
Series B Preferred pursuant to the Purchase Agreement and (c) the New Investors.
5. Effect of Amendment. Except as amended as set forth above, the
Agreement shall continue in full force and effect.
6. Intent of the Parties. The Parties intend that the Recitals
set forth in this Agreement shall be part of this Agreement.
7. Counterparts. This Amendment may be signed in one or more
counterparts, each of which shall be deemed an original and all of which, taken
together, shall be deemed one and the same documents.
2
33
IN WITNESS WHEREOF, the parties hereto have executed this Amendment as
of the day and year first above written.
ATHEROGENICS, INC.
By: /s/ Xxxxxxx X Xxxxxxx MD PhD
-----------------------------------------
Name: XXXXXXX X XXXXXXX MD PHD
---------------------------------------
Title: PRESIDENT & CEO
--------------------------------------
ALLIANCE TECHNOLOGY VENTURES, L.P.
ATV/GP PARALLEL FUND, L.P.
ATV/MFJ PARALLEL FUND, L.P.
By: /s/ Xxxxxxx X Xxxxx
-----------------------------------------
Name: Xxxxxxx X Xxxxx
---------------------------------------
Title: Managing Gen. Partner
--------------------------------------
INTELLIGENT SYSTEMS CORPORATION
By: /s/ J. Xxxxxx Xxxxxxx
-----------------------------------------
Name: J. Xxxxxx Xxxxxxx
---------------------------------------
Title: President
--------------------------------------
INTERNATIONAL MUREX TECHNOLOGIES
CORPORATION
By: /s/ X. X. Xxxxxx
-----------------------------------------
Name: X. X. Xxxxxx
---------------------------------------
Title: President/CEO
--------------------------------------
NEW YORK LIFE INSURANCE COMPANY
By: /s/ Xxxxxxxxx X. Xxxxx
-----------------------------------------
Name: Xxxxxxxxx X. Xxxxx
---------------------------------------
Title: Assistant Vice President
--------------------------------------
S-1
34
SANDERLING III LIMITED PARTNERSHIP
SANDERLING VENTURE PARTNERS III, L.P.
SANDERLING III BIOMEDICAL, L.P.
SANDERLING VENTURES MANAGEMENT
By:
-----------------------------------------
Name:
---------------------------------------
Title:
--------------------------------------
PHOENIX LEASING INCORPORATED
By: /s/ N. H. Xxxxxx
-----------------------------------------
Name: N. H. Xxxxxx
---------------------------------------
Title: Vice President
--------------------------------------
DP III ASSOCIATES, L.P.
By: One Xxxxxx Square Associates, L.P.
Its: General Partner
By: /s/ Xxxxxxxx X. Xxxxxxxxxx
-----------------------------------------
Name: Xxxxxxxx X. Xxxxxxxxxx
---------------------------------------
Title: General Partner
--------------------------------------
BIOTECHNOLOGY INVESTMENTS LIMITED
By: Old Court Limited
Its: Custodian
----------------------------------------
By: /s/ Xxxxxxxx X. Xxxxxxxxxx
-----------------------------------------
Name: Xxxxxxxx X. Xxxxxxxxxx
---------------------------------------
Title: Attorney-in-Fact
--------------------------------------
S-2
35
DOMAIN PARTNERS III, L.P.
By: One Xxxxxx Square Associates III, L.P.
Its: General Partner
By: /s/ Xxxxxxxx X. Xxxxxxxxxx
-----------------------------------------
Name: Xxxxxxxx X. Xxxxxxxxxx
---------------------------------------
Title: General Partner
--------------------------------------
SPROUT CAPITAL VII, L.P.
By: DLJ Capital Corp.
Its: Managing General Partner
By: /s/ Xxxxxxxx Xxxxxxx, M.D., Ph.D.
-----------------------------------------
Name: Xxxxxxxx Xxxxxxx, M.D., Ph.D.
---------------------------------------
Title: Attorney-in-Fact
--------------------------------------
SPROUT CEO FUND, L.P.
By: DLJ Capital Corp.
Its: General Partner
By: /s/ Xxxxxxxx Xxxxxxx, M.D., Ph.D.
-----------------------------------------
Name: Xxxxxxxx Xxxxxxx, M.D., Ph.D.
---------------------------------------
Title: Attorney-in-Fact
--------------------------------------
DLJ CAPITAL CORP.
By: /s/ Xxxxxxxx Xxxxxxx, M.D., Ph.D.
-----------------------------------------
Name: Xxxxxxxx Xxxxxxx, M.D., Ph.D.
---------------------------------------
Title: Attorney-in-Fact
--------------------------------------
X-0
00
XXX FIRST ESC, L.L.C.
By: DLJ LBO Plans Management Corporation
Its: Manager
By: /s/ Xxxxxxxx Xxxxxxx, M.D., Ph.D.
-----------------------------------------
Name: Xxxxxxxx Xxxxxxx, M.D., Ph.D.
---------------------------------------
Title: Attorney-in-Fact
--------------------------------------
/s/ Xxx X. Xxxxxx
--------------------------------------------
Xxx X. Xxxxxx
/s/ Xxxxxx X. Xxxxxx
--------------------------------------------
Xxxxxx X. Xxxxxx
/s/ Xxx X. Xxxx
--------------------------------------------
Xxx X. Xxxx
/s/ Xxxxxx X. Xxxxxx
--------------------------------------------
Xxxxxx X. Xxxxxx
S-4
37
THIRD AMENDMENT TO AMENDED AND RESTATED
MASTER RIGHTS AGREEMENT
THIS THIRD AMENDMENT TO AMENDED AND RESTATED MASTER RIGHTS AGREEMENT
(the "Amendment"), dated as of April 13, 1999, is entered into by and among
ATHEROGENICS, INC., a Georgia corporation (the "Company"), and the other parties
listed on the signature pages hereto, with respect to the Amended and Restated
Master Rights Agreement, dated as of October 31, 1995, by and among the Company
and the other parties thereto, as amended (the "Agreement").
RECITALS
WHEREAS, the Company intends to sell shares of its Series C Convertible
Preferred Stock (the "Series C Preferred") to certain purchasers (the
"Purchasers") pursuant to the terms of a Series C Convertible Preferred Stock
Purchase Agreement dated of even date herewith (the "Purchase Agreement");
WHEREAS, pursuant to the terms of the Purchase Agreement, the
Purchasers must be added as parties to the Agreement;
WHEREAS, to add the Purchasers as parties to the Agreement requires
certain amendments to the Agreement;
WHEREAS, pursuant to Section 5.8 of the Agreement, the Agreement may be
amended only with the written consent of the Company and the holders of at least
66-2/3% of the Registrable Stock then in existence; and
WHEREAS, in order to add the Purchasers as parties to the Agreement and
to make certain other amendments to the Agreement, the parties hereto desire to
enter into this Amendment in accordance with Section 5.8 of the Agreement;
NOW, THEREFORE, for and in consideration of the premises, the
agreements and covenants set forth herein, and other consideration, the receipt
and sufficiency of which are hereby acknowledged, the parties hereto agree as
follows:
1. Definitions. All capitalized terms used herein without
definition shall have the meanings ascribed to them in the Agreement.
2. Amendments. The Agreement is hereby amended as follows:
(a) Section 1.1(l) is amended in its entirety to read as
follows:
(1) "Investors." The term "Investors" shall mean
Alliance, ATV/GP, ATV/MFJ, Intelligent Systems, Murex,
Sanderling Limited, Sanderling Venture, Sanderling Biomedical,
Sanderling Management, NY Life , Phoenix Leasing Incorporated,
Sprout Capital VII, L.P., Sprout CEO Fund, L.P., DLJ Capital
Corp., DLJ First ESC L.L.C., DP III Associates, L.P., Old
Court Limited, Domain
38
Partners III, L.P., Xxx X. Xxxxxx, Xxxxxx X. Xxxxxx, Xxx X.
Xxxx, Xxxxxx X. Xxxxxx, Long Xxxxxxxx & Xxxxxx LLP, Xxxxxxx
Technology Partners, L.P., Live Oak Equity Partners, L.P.,
Sentron Medical, Inc., Trustees of Boston University, Pacific
Horizons Partners II L.P., Pacific Horizons Partners III L.P.,
their respective successors and assigns and any other holder
of Preferred Stock who by amendment is added as a party to
this Agreement.
(b) Section 1.1(o) is hereby amended in its entirety to
read as follows:
(o) "Permitted Transferees." The term "Permitted
Transferees" of an Investor shall mean (i)
any other Investor; (ii) any Affiliate of
any Investor; (iii) any one or more members
of a class consisting of the spouse,
children and grandchildren of an Investor,
or a trust for the benefit of any one or
more members of such class; or (iv) any
shareholder or partner of any non-natural
Investor upon a distribution by a
partnership to its partners or otherwise
upon the dissolution or liquidation of the
non-natural Investor.
(c) Section 1.1(q) is hereby amended in its entirety to
read as follows:
(q) "Preferred Stock." The term "Preferred
Stock" shall mean the Company's Series A
Convertible Preferred Stock, Series B
Convertible Preferred Stock and Series C
Convertible Preferred Stock.
(d) Sections 2.1(b) and 2.1(c) are hereby amended by
deleting from each such section the percentage "7.5%" and replacing it
with the percentage "3.0%".
(e) Section 2.2(c)(x) is hereby amended by deleting
therefrom the number "3,053,334" and replacing it with the number
"4,854,316".
(f) Section 2.2(c) is hereby amended by adding a new
subparagraph (xi) to that section which shall be and read in its
entirety as follows:
"(xi) the issuance is of shares of Series C
Convertible Preferred Stock at a price per share of
not less than $3.00, provided, that the total of all
such shares does not exceed 4,715,385 shares."
(g) Section 3.1(a) is hereby amended by deleting
therefrom the date "January 1, 2001" and replacing it with the date
"April 15, 2004".
3. Purchasers. Upon the effectiveness of this Amendment, as
provided in Section 4 hereof, the Purchasers shall have all of the rights and
privileges and shall be bound by all of the terms and conditions of the
Agreement applicable to Investors.
2
39
4. Effectiveness. This Amendment shall become effective upon the
execution hereof by (a) the Company, (b) the holders of 66-2/3% of the
Registrable Stock outstanding immediately prior to the issuance of shares of
Series C Preferred pursuant to the Purchase Agreement and (c) the Purchasers.
5. Effect of Amendment. Except as amended as set forth above, the
Agreement shall continue in full force and effect.
6. Intent of the Parties. The Parties intend that the Recitals
set forth in this Agreement shall be part of this Agreement.
7. Counterparts. This Amendment may be signed in one or more
counterparts, each of which shall be deemed an original and all of which, taken
together, shall be deemed one and the same Amendment.
IN WITNESS WHEREOF, the parties hereto have executed this Amendment as
of the day and year first above written.
ATHEROGENICS, INC.
By: /s/ X.X. Xxxxxxxxx
---------------------------------------
Name: X.X. Xxxxxxxxx
-------------------------------------
Title: Vice President
------------------------------------
ALLIANCE TECHNOLOGY VENTURES, L.P.
ATV/GP PARALLEL FUND, L.P.
ATV/MFJ PARALLEL FUND, L.P.
By: /s/ Xxxxxxx X. Xxxxx
---------------------------------------
Name: Xxxxxxx X. Xxxxx
-------------------------------------
Title: Managing G.P.
------------------------------------
INTELLIGENT SYSTEMS CORPORATION
By: /s/
---------------------------------------
Name:
-------------------------------------
Title:
------------------------------------
INTERNATIONAL MUREX TECHNOLOGIES
CORPORATION
By:
---------------------------------------
Name:
-------------------------------------
Title:
------------------------------------
[Signatures continued on following page]
S-1
40
NEW YORK LIFE INSURANCE COMPANY
By: /s/ Xxxxxxx X. Xxxxx
---------------------------------------
Name: Xxxxxxx X. Xxxxx
-------------------------------------
Title: Director, Venture Capital
------------------------------------
SANDERLING III LIMITED PARTNERSHIP
SANDERLING VENTURE PARTNERS III, L.P.
SANDERLING III BIOMEDICAL, L.P.
SANDERLING VENTURES MANAGEMENT
By:
---------------------------------------
Name:
-------------------------------------
Title:
------------------------------------
PHOENIX LEASING INCORPORATED
By:
---------------------------------------
Name:
-------------------------------------
Title:
------------------------------------
DP III ASSOCIATES, L.P.
By: One Xxxxxx Square Associates, L.P.
Its: General Partner
By: /s/ Xxxxxxxx X. Xxxxxxxxxx
---------------------------------------
Name: Xxxxxxxx X. Xxxxxxxxxx
-------------------------------------
Title: General Partner
------------------------------------
BIOTECHNOLOGY INVESTMENTS LIMITED
By: Old Court Limited
Its: Custodian
---------------------------------------
By: /s/ Xxxxxxxx X. Xxxxxxxxxx
---------------------------------------
Name: Xxxxxxxxx X. Xxxxxxxxxx
-------------------------------------
Title: Attorney-In-Fact
------------------------------------
[Signatures continued on following page]
S-2
41
DOMAIN PARTNERS III, L.P.
By: One Xxxxxx Square Associates III, L.P.
Its: General Partner
By: /s/ Xxxxxxxx X. Xxxxxxxxxx
---------------------------------------
Name: Xxxxxxxx X. Xxxxxxxxxx
-------------------------------------
Title: General Partner
------------------------------------
SPROUT CAPITAL VII, L.P.
By: DLJ Capital Corp.
Its: Managing General Partner
By: /s/
---------------------------------------
Name:
-------------------------------------
Title:
------------------------------------
SPROUT CEO FUND, L.P.
By: DLJ Capital Corp.
Its: General Partner
By: /s/
---------------------------------------
Name:
-------------------------------------
Title:
------------------------------------
DLJ CAPITAL CORP.
By: /s/
---------------------------------------
Name:
-------------------------------------
Title:
------------------------------------
[Signatures continued on following page]
X-0
00
XXX FIRST ESC, L.L.C.
By: DLJ LBO Plans Management Corporation
Its: Manager
By: /s/
-------------------------------------
Name:
-------------------------------------
Title:
------------------------------------
------------------------------------------
Xxx X. Xxxxxx
------------------------------------------
Xxxxxx X. Xxxxxx
------------------------------------------
Xxx X. Xxxx
/s/ Xxxxxx X. Xxxxxx
------------------------------------------
Xxxxxx X. Xxxxxx
XXXXXXX TECHNOLOGY PARTNERS, L.P.
By: /s/
---------------------------------------
Name:
-------------------------------------
Title: Managing Partner
------------------------------------
LIVE OAK EQUITY PARTNERS, L.P.
By: /s/ Xxxxxx Xxxxxxxxxxxx
---------------------------------------
Name: Xxxxxx Xxxxxxxxxxxx
-------------------------------------
Title: General Partner
------------------------------------
[Signatures continued on following page]
S-4
43
SENTRON MEDICAL, INC.
By: /s/ Xxxxxx X. Xxxxxx
-------------------------------------------
Name: Xxxxxx X. Xxxxxx
-----------------------------------------
Title: Group Director Venture Projects
----------------------------------------
TRUSTEES OF BOSTON UNIVERSITY
By: /s/ Xxxxxxx X. Xxxxx
-------------------------------------------
Name: Xxxxxxx X. Xxxxx
-----------------------------------------
Title: Assistant Treasurer/Boston University
----------------------------------------
PACIFIC HORIZONS PARTNERS II L.P.
By: /s/ Xxxxxx X. Xxxxx
-------------------------------------------
Name: Xxxxxx X. Xxxxx
-----------------------------------------
Title: General Partner
----------------------------------------
PACIFIC HORIZONS PARTNERS III L.P.
By: /s/ Xxxxxx X. Xxxxx
-------------------------------------------
Name: Xxxxxx X. Xxxxx
-----------------------------------------
Title: General Partner
----------------------------------------
LONG XXXXXXXX & XXXXXX LLP
By: /s/ Xxxxxxx X. Xxxxxxxxxxx
-------------------------------------------
Name: Xxxxxxx X. Xxxxxxxxxxx
-----------------------------------------
Title: Partner
----------------------------------------
X-0
00
XXXXXX XXXXXXXXX TO AMENDED AND RESTATED
MASTER RIGHTS AGREEMENT
THIS FOURTH AMENDMENT TO AMENDED AND RESTATED MASTER RIGHTS AGREEMENT
(the "Amendment"), dated as of May 11, 1999, is entered into by and among
ATHEROGENICS, INC., a Georgia corporation (the "Company"), and the other parties
listed on the signature pages hereto, with respect to the Amended and Restated
Master Rights Agreement, dated as of October 31, 1995, by and among the Company
and the other parties thereto, as amended (the "Agreement").
RECITALS
WHEREAS, the Company intends to sell shares of its Series C Convertible
Preferred Stock (the "Series C Preferred") to certain purchasers (the
"Purchasers") pursuant to the terms of a Series C Convertible Preferred Stock
Purchase Agreement dated of even date herewith (the "Purchase Agreement");
WHEREAS, pursuant to the terms of the Purchase Agreement, the
Purchasers must be added as parties to the Agreement;
WHEREAS, to add the Purchasers as parties to the Agreement requires
certain amendments to the Agreement;
WHEREAS, pursuant to Section 5.8 of the Agreement, the Agreement may be
amended only with the written consent of the Company and the holders of at least
66-2/3% of the Registrable Stock then in existence; and
WHEREAS, in order to add the Purchasers as parties to the Agreement and
to make certain other amendments to the Agreement, the parties hereto desire to
enter into this Amendment in accordance with Section 5.8 of the Agreement;
NOW, THEREFORE, for and in consideration of the premises, the
agreements and covenants set forth herein, and other consideration, the receipt
and sufficiency of which are hereby acknowledged, the parties hereto agree as
follows:
1. Definitions. All capitalized terms used herein without
definition shall have the meanings ascribed to them in the Agreement.
2. Amendments. The Agreement is hereby amended as follows:
(a) Section 1.1(l) is amended in its entirety to read as
follows:
(1) "Investors." The term "Investors" shall mean
Alliance, ATV/GP, ATV/MFJ, Intelligent Systems, Murex,
Sanderling Limited, Sanderling Venture, Sanderling Biomedical,
Sanderling Management, NY Life , Phoenix Leasing Incorporated,
Sprout Capital VII, L.P., Sprout CEO Fund, L.P., DLJ Capital
Corp., DLJ First ESC L.L.C., DP III Associates, L.P., Old
Court Limited, Domain
45
Partners III, L.P., Xxx X. Xxxxxx, Xxxxxx X. Xxxxxx, Xxx X.
Xxxx, Xxxxxx X. Xxxxxx, Long Xxxxxxxx & Xxxxxx LLP, Xxxxxxx
Technology Partners, L.P., Live Oak Equity Partners, L.P.,
Sentron Medical, Inc., Trustees of Boston University, Pacific
Horizons Partners II L.P., Pacific Horizons Partners III L.P.,
Zeist Foundation, Inc., Xxxxxx X. Xxxxxxx, Xx. and Xxxx X.
Xxxxxxx, Joint Tenants with Right of Survivorship, Xxxxxx
Xxxxxxx Xxxxxxx III, Oakwood Medical Investors II, L.L.C.,
Community Investment Partners III L.P., LLLP, their respective
successors and assigns and any other holder of Preferred Stock
who by amendment is added as a party to this Agreement.
(b) Section 2.2(c)(xi) is hereby amended by deleting therefrom
the number "4,715,385" and replacing it with the number "7,500,000".
3. Purchasers. Upon the effectiveness of this Amendment, as
provided in Section 4 hereof, the Purchasers shall have all of the rights and
privileges and shall be bound by all of the terms and conditions of the
Agreement applicable to Investors.
4. Effectiveness. This Amendment shall become effective upon the
execution hereof by (a) the Company, (b) the holders of 66-2/3% of the
Registrable Stock outstanding immediately prior to the issuance of shares of
Series C Preferred pursuant to the Purchase Agreement and (c) the Purchasers.
5. Effect of Amendment. Except as amended as set forth above, the
Agreement shall continue in full force and effect.
6. Intent of the Parties. The Parties intend that the Recitals
set forth in this Agreement shall be part of this Agreement.
7. Counterparts. This Amendment may be signed in one or more
counterparts, each of which shall be deemed an original and all of which, taken
together, shall be deemed one and the same Amendment.
IN WITNESS WHEREOF, the parties hereto have executed this Amendment as
of the day and year first above written.
ATHEROGENICS, INC.
By: /s/ X. X. Xxxxxxxxx
-----------------------------------------
Name: X. X. Xxxxxxxxx
---------------------------------------
Title: Vice President
--------------------------------------
ALLIANCE TECHNOLOGY VENTURES, L.P.
ATV/GP PARALLEL FUND, L.P.
ATV/MFJ PARALLEL FUND, L.P.
By: /s/ Xxxxxxx X. Xxxxx
-----------------------------------------
Name:
---------------------------------------
Title:
--------------------------------------
[Signatures continued on following page]
S-1
46
INTELLIGENT SYSTEMS CORPORATION
By: /s/ Xxxxxx X. Xxxxxx
-----------------------------------------
Name: Xxxxxx X. Xxxxxx
---------------------------------------
Title: Vice President
--------------------------------------
INTERNATIONAL MUREX TECHNOLOGIES
CORPORATION
By:
-----------------------------------------
Name:
---------------------------------------
Title:
--------------------------------------
NEW YORK LIFE INSURANCE COMPANY
By: /s/ Xxxxxxx X. Xxxxx
-----------------------------------------
Name: XXXXXXX X. XXXXX
---------------------------------------
Title: DIRECTOR, VENTURE CAPITAL
--------------------------------------
SANDERLING III LIMITED PARTNERSHIP
SANDERLING VENTURE PARTNERS III, L.P.
SANDERLING III BIOMEDICAL, L.P.
SANDERLING VENTURES MANAGEMENT
By: /s/ Xxxxxx XxXxxx
-----------------------------------------
Name: Xxxxxx XxXxxx
---------------------------------------
Title: General Partner
--------------------------------------
PHOENIX LEASING INCORPORATED
By:
-----------------------------------------
Name:
---------------------------------------
Title:
--------------------------------------
[Signatures continued on following page]
X-0
00
XX XXX ASSOCIATES, L.P.
By: One Xxxxxx Square Associates III, L.P.
Its: General Partner
By: /s/ Xxxxxxxx X. Xxxxxxxxxx
-----------------------------------------
Name: Xxxxxxxx X. Xxxxxxxxxx
---------------------------------------
Title: General Partner
--------------------------------------
BIOTECHNOLOGY INVESTMENTS LIMITED
By: Old Court Limited
Its: Custodian
By: /s/ Xxxxxxxx X. Xxxxxxxxxx
-----------------------------------------
Name: Xxxxxxxx X. Xxxxxxxxxx
---------------------------------------
Title: Attorney-In-Fact
--------------------------------------
DOMAIN PARTNERS III, L.P.
By: One Xxxxxx Square Associates III, L.P.
Its: General Partner
By: /s/ Xxxxxxxx X. Xxxxxxxxxx
-----------------------------------------
Name: Xxxxxxxx X. Xxxxxxxxxx
---------------------------------------
Title: General Partner
--------------------------------------
SPROUT CAPITAL VII, L.P.
By: DLJ Capital Corp.
Its: Managing General Partner
By: /s/ Xxxxxxxx X. Xxxxxxx
-----------------------------------------
Name: Xxxxxxxx X. Xxxxxxx
---------------------------------------
Title: Attorney-In-Fact
--------------------------------------
[Signatures continued on following page]
S-3
48
SPROUT CEO FUND, L.P.
By: DLJ Capital Corp.
Its: General Partner
By: /s/ Xxxxxxxx X. Xxxxxxx
-----------------------------------------
Name: Xxxxxxxx X. Xxxxxxx
---------------------------------------
Title: Attorney-In-Fact
--------------------------------------
DLJ CAPITAL CORP.
By: /s/ Xxxxxxxx X. Xxxxxxx
-----------------------------------------
Name: Xxxxxxxx X. Xxxxxxx
---------------------------------------
Title: Attorney-In-Fact
--------------------------------------
DLJ FIRST ESC, L.L.C.
By: DLJ LBO Plans Management Corporation
Its: Manager
By: /s/ Xxxxxxxx X. Xxxxxxx
-----------------------------------------
Name: Xxxxxxxx X. Xxxxxxx
---------------------------------------
Title: Attorney-In-Fact
--------------------------------------
--------------------------------------------
Xxx X. Xxxxxx
/s/ Xxxxxx X. Xxxxxx
--------------------------------------------
Xxxxxx X. Xxxxxx
/s/ Xxxxxx X. Xxxx
--------------------------------------------
Xxx X. Xxxx
/s/ Xxxxxx X. Xxxxxx
--------------------------------------------
Xxxxxx X. Xxxxxx
[Signatures continued on following page]
X-0
00
XXXXXXX TECHNOLOGY PARTNERS, L.P.
By: /s/
--------------------------------------------
Name:
------------------------------------------
Title: Managing Partner
-----------------------------------------
LIVE OAK EQUITY PARTNERS, L.P.
By: /s/
--------------------------------------------
Name:
------------------------------------------
Title: General Partner
-----------------------------------------
SENTRON MEDICAL, INC.
By: /s/ Xxxxxxx X. Xxxxxxx
--------------------------------------------
Name: Xxxxxxx X. Xxxxxxx
------------------------------------------
Title: Vice President for Sentron Medical, Inc.
-----------------------------------------
TRUSTEES OF BOSTON UNIVERSITY
By: /s/ Xxxxxxx X. Xxxxx
--------------------------------------------
Name: Xxxxxxx X. Xxxxx
------------------------------------------
Title: Assistant Treasurer
-----------------------------------------
PACIFIC HORIZONS PARTNERS II L.P.
By: /s/
--------------------------------------------
Name:
------------------------------------------
Title: General Partner
-----------------------------------------
PACIFIC HORIZONS PARTNERS III L.P.
By: /s/
--------------------------------------------
Name:
------------------------------------------
Title: General Partner
-----------------------------------------
[Signatures continued on following page]
X-0
00
XXXX XXXXXXXX & XXXXXX LLP
By: /s/ Xxxxxxx X. Xxxxxxxxxxx
-----------------------------------------
Name: Xxxxxxx X. Xxxxxxxxxxx
---------------------------------------
Title: Partner
--------------------------------------
ZEIST FOUNDATION, INC.
By: /s/ Xxxxxx X. Xxxxxxx, Xx.
-----------------------------------------
Name: Xxxxxx X. Xxxxxxx, Xx.
---------------------------------------
Title: President
--------------------------------------
/s/ Xxxxxx X. Xxxxxxx, Xx.
--------------------------------------------
Xxxxxx X. Xxxxxxx, Xx.
/s/ Xxxx X. Xxxxxxx
--------------------------------------------
Xxxx X. Xxxxxxx
/s/ Xxxxxx Xxxxxxx Xxxxxxx III
--------------------------------------------
Xxxxxx Xxxxxxx Xxxxxxx III
OAKWOOD MEDICAL INVESTORS II, L.L.C.
By: /s/ Xxxx X. Xxxxx, M.D.
-----------------------------------------
Name: Xxxx X. Xxxxx, M.D.
---------------------------------------
Title:
--------------------------------------
COMMUNITY INVESTMENT
PARTNERS III L.P., LLLP
By: /s/ Xxxxxx X. Xxxxxxxxx
-----------------------------------------
Name: Xxxxxx X. Xxxxxxxxx
---------------------------------------
Title: President
--------------------------------------
S-6
51
FIFTH AMENDMENT TO AMENDED AND RESTATED
MASTER RIGHTS AGREEMENT
THIS FIFTH AMENDMENT TO AMENDED AND RESTATED MASTER
RIGHTS AGREEMENT (the "Amendment"), dated as of August 30, 1999, is entered
into by and among ATHEROGENICS, INC., a Georgia corporation (the "Company"),
and the other parties listed on the signature pages hereto, with respect to the
Amended and Restated Master Rights Agreement, dated as of October 31, 1995, by
and among the Company and the other parties thereto, as amended (the
"Agreement").
RECITALS
WHEREAS, the Company intends to sell shares of its Series C
Convertible Preferred Stock (the "Series C Preferred") to Xxxxxxx Xxxxx Capital
Partners VI, L.P. (the "Purchaser") pursuant to the terms of a Series C
Convertible Preferred Stock Purchase Agreement dated of even date herewith (the
"Purchase Agreement");
WHEREAS, pursuant to the terms of the Purchase Agreement, the
Purchaser must be added as a party to the Agreement;
WHEREAS, to add the Purchaser as a party to the Agreement requires
certain amendments to the Agreement;
WHEREAS, pursuant to Section 5.8 of the Agreement, the Agreement may
be amended only with the written consent of the Company and the holders of at
least 66-2/3% of the Registrable Stock then in existence; and
WHEREAS, in order to add the Purchaser as a party to the Agreement and
to make certain other amendments to the Agreement, the parties hereto desire to
enter into this Amendment in accordance with Section 5.8 of the Agreement;
NOW, THEREFORE, for and in consideration of the premises, the
agreements and covenants set forth herein, and other consideration, the receipt
and sufficiency of which are hereby acknowledged, the parties hereto agree as
follows:
1. Definitions. All capitalized terms used herein without
definition shall have the meanings ascribed to them in the Agreement.
2. Amendments. The Agreement is hereby amended as follows:
(a) Section 1.1(l) is amended in its entirety to read as
follows:
(1) "Investors." The term "Investors" shall
mean Alliance, ATV/GP, ATV/MFJ, Intelligent Systems, Murex,
Sanderling Limited, Sanderling Venture,
52
Sanderling Biomedical, Sanderling Management, NY Life ,
Phoenix Leasing Incorporated, Sprout Capital VII, L.P.,
Sprout CEO Fund, L.P., DLJ Capital Corp., DLJ First ESC
L.L.C., DP III Associates, L.P., Old Court Limited, Domain
Partners III, L.P., Xxx X. Xxxxxx, Xxxxxx X. Xxxxxx, Xxx X.
Xxxx, Xxxxxx X. Xxxxxx, Long Xxxxxxxx & Xxxxxx LLP, Xxxxxxx
Technology Partners, L.P., Live Oak Equity Partners, L.P.,
Sentron Medical, Inc., Trustees of Boston University, Pacific
Horizons Partners II L.P., Pacific Horizons Partners III
L.P., Zeist Foundation, Inc., Xxxxxx X. Xxxxxxx, Xx. and Xxxx
X. Xxxxxxx, Joint Tenants with Right of Survivorship, Xxxxxx
Xxxxxxx Xxxxxxx III, Oakwood Medical Investors II, L.L.C.,
Community Investment Partners III L.P., LLLP, Xxxxxxx Xxxxx
Capital Partners VI, L.P., their respective successors and
assigns and any other holder of Preferred Stock who by
amendment is added as a party to this Agreement.
(b) Section 2.2(c)(xi) is hereby amended by deleting
therefrom the number "7,500,000" and replacing it with the number
"8,500,000".
3. Purchaser. Upon the effectiveness of this Amendment, as
provided in Section 4 hereof, the Purchaser shall have all of the rights and
privileges and shall be bound by all of the terms and conditions of the
Agreement applicable to Investors.
4. Effectiveness. This Amendment shall become effective upon the
execution hereof by (a) the Company, (b) the holders of 66-2/3% of the
Registrable Stock outstanding immediately prior to the issuance of shares of
Series C Preferred pursuant to the Purchase Agreement and (c) the Purchaser.
5. Effect of Amendment. Except as amended as set forth above,
the Agreement shall continue in full force and effect.
6. Intent of the Parties. The Parties intend that the Recitals
set forth in this Agreement shall be part of this Agreement.
7. Counterparts. This Amendment may be signed in one or more
counterparts, each of which shall be deemed an original and all of which, taken
together, shall be deemed one and the same Amendment.
IN WITNESS WHEREOF, the parties hereto have executed this Amendment as
of the day and year first above written.
ATHEROGENICS, INC.
By: /s/ X. X. Xxxxxxxxx
-----------------------
Name: X. X. Xxxxxxxxx
-----------------------
Title: Vice President
-----------------------
[Signatures continued on following page]
S-1
53
ALLIANCE TECHNOLOGY VENTURES, L.P.
ATV/GP PARALLEL FUND, L.P.
ATV/MFJ PARALLEL FUND, L.P.
By: /s/
---------------------------------------
Name:
-------------------------------------
Title:
------------------------------------
INTELLIGENT SYSTEMS CORPORATION
By: /s/
---------------------------------------
Name: X. X.
-------------------------------------
Title:
------------------------------------
INTERNATIONAL MUREX TECHNOLOGIES
CORPORATION
By:
--------------------------------------
Name:
------------------------------------
Title:
-----------------------------------
NEW YORK LIFE INSURANCE COMPANY
By:/s/ Xxxxxxx Xxxxx
---------------------------------------
Name: Xxxxxxx X. Xxxxx
-------------------------------------
Title: Director, Venture Capital
------------------------------------
SANDERLING III LIMITED PARTNERSHIP
SANDERLING VENTURE PARTNERS III, L.P.
SANDERLING III BIOMEDICAL, L.P.
SANDERLING VENTURES MANAGEMENT
By:/s/ Xxxx X. Xxxxxxxxx
---------------------------------------
Name: Xxxx X. Xxxxxxxxx
-------------------------------------
Title: General Partner
------------------------------------
[Signatures continued on following page]
S-2
54
PHOENIX LEASING INCORPORATED
By:
---------------------------------------
Name:
-------------------------------------
Title:
------------------------------------
DP III ASSOCIATES, L.P.
By: One Xxxxxx Square Associates III, L.P.
Its: General Partner
By:/s/ Xxxxxxxx X. Xxxxxxxxxx
---------------------------------------
Name: Xxxxxxxx X. Xxxxxxxxxx
-------------------------------------
Title: General Partner
------------------------------------
BIOTECHNOLOGY INVESTMENTS LIMITED
By: Old Court Limited
Its: Custodian
--------------------------------------
By:/s/ Xxxxxxxx X. Xxxxxxxxxx
---------------------------------------
Name: Xxxxxxxx X. Xxxxxxxxxx
-------------------------------------
Title: Attorney-In-Fact
------------------------------------
DOMAIN PARTNERS III, L.P.
By: One Xxxxxx Square Associates III, L.P.
Its: General Partner
By:/s/ Xxxxxxxx X. Xxxxxxxxxx
---------------------------------------
Name: Xxxxxxxx X. Xxxxxxxxxx
-------------------------------------
Title: General Partner
------------------------------------
[Signatures continued on following page]
X-0
00
XXXXXX XXXXXXX XXX, X.X.
By: DLJ Capital Corp.
Its: Managing General Partner
By:/s/ Xxxxxxxx X. Xxxxxxx
---------------------------------------
Name: Xxxxxxxx X. Xxxxxxx
-------------------------------------
Title: Attorney-In-Fact
------------------------------------
SPROUT CEO FUND, L.P.
By: DLJ Capital Corp.
Its: General Partner
By:/s/ Xxxxxxxx X. Xxxxxxx
---------------------------------------
Name: Xxxxxxxx X. Xxxxxxx
-------------------------------------
Title: Attorney-In-Fact
------------------------------------
DLJ CAPITAL CORP.
By:/s/ Xxxxxxxx X. Xxxxxxx
---------------------------------------
Name: Xxxxxxxx X. Xxxxxxx
-------------------------------------
Title: Attorney-In-Fact
------------------------------------
DLJ FIRST ESC, L.L.C.
By: DLJ LBO Plans Management Corporation
Its: Manager
By:/s/ Xxxxxxxx X. Xxxxxxx
---------------------------------------
Name: Xxxxxxxx X. Xxxxxxx
-------------------------------------
Title: Attorney-In-Fact
------------------------------------
------------------------------------------
Xxx X. Xxxxxx
[Signatures continued on following page]
S-4
56
/s/ Xxxxxx X. Xxxxxx
------------------------------------------
Xxxxxx X. Xxxxxx
/s/ Xxxxxx X. Xxxx
------------------------------------------
Xxx X. Xxxx
/s/ Xxxxxx X. Xxxxxx
------------------------------------------
Xxxxxx X. Xxxxxx
XXXXXXX TECHNOLOGY PARTNERS, L.P.
By:
---------------------------------------
Name:
-------------------------------------
Title: Managing Partner
------------------------------------
LIVE OAK EQUITY PARTNERS, L.P.
By:
---------------------------------------
Name: Murali
-------------------------------------
Title: General Partner
------------------------------------
SENTRON MEDICAL, INC.
By:/s/ Xxxxxx X. Xxxxxx
---------------------------------------
Name: Xxxxxx X. Xxxxxx
-------------------------------------
Title: Group Director, Venture Projects
------------------------------------
TRUSTEES OF BOSTON UNIVERSITY
By:/s/ Xxxxxxx X. Xxxxx
---------------------------------------
Name: Xxxxxxx X. Xxxxx
-------------------------------------
Title: Assistant Treasurer
Boston University
------------------------------------
[Signatures continued on following page]
S-5
57
PACIFIC HORIZONS PARTNERS II L.P.
By:/s/ Xxxxxx X. Xxxxx
---------------------------------------
Name: Xxxxxx X. Xxxxx
-------------------------------------
Title: G. P.
------------------------------------
PACIFIC HORIZONS PARTNERS III L.P.
By:/s/ Xxxxxx X. Xxxxx
---------------------------------------
Name: Xxxxxx X. Xxxxx
-------------------------------------
Title: G. P.
------------------------------------
LONG XXXXXXXX & XXXXXX LLP
By:/s/ Xxxxxxx X. Xxxxxxxxxxx
---------------------------------------
Name: Xxxxxxx X. Xxxxxxxxxxx
-------------------------------------
Title: Partner
------------------------------------
ZEIST FOUNDATION, INC.
By:/s/ Xxxxxx X. Xxxxxxx, Xx.
---------------------------------------
Name: Xxxxxx X. Xxxxxxx, Xx.
-------------------------------------
Title: Co-President
------------------------------------
/s/ Xxxxxx X. Xxxxxxx, Xx.
------------------------------------------
Xxxxxx X. Xxxxxxx, Xx.
/s/ Xxxx X. Xxxxxxx
------------------------------------------
Xxxx X. Xxxxxxx
/s/ Xxxxxx X. Xxxxxxx III
------------------------------------------
Xxxxxx Xxxxxxx Xxxxxxx III
[Signatures continued on following page]
S-6
58
OAKWOOD MEDICAL INVESTORS II, L.L.C.
By:/s/ Xxxx X. Xxxxx, M. D.
---------------------------------------
Name: Xxxx X. Xxxxx, M. D.
-------------------------------------
Title: Manager
------------------------------------
COMMUNITY INVESTMENT
PARTNERS III L.P., LLLP
By:/s/ Xxx Xxxxxxxxx
---------------------------------------
Name: Xxx Xxxxxxxxx
-------------------------------------
Title: Chairman
------------------------------------
XXXXXXX XXXXX CAPITAL PARTNERS VI, L.P.
By:/s/ A. M. Minocherhomjee
---------------------------------------
Name: Xxxx X. Xxxxxxxxxxxxxx
-------------------------------------
Title: Managing Director
------------------------------------
S-7
